0001493152-22-021543.txt : 20220808 0001493152-22-021543.hdr.sgml : 20220808 20220805205545 ACCESSION NUMBER: 0001493152-22-021543 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BLUE BIOFUELS, INC. CENTRAL INDEX KEY: 0001549145 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 454944960 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54942 FILM NUMBER: 221142183 BUSINESS ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 BUSINESS PHONE: (888)607-3555 MAIL ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: ALLIANCE BIOENERGY PLUS, INC. DATE OF NAME CHANGE: 20141204 FORMER COMPANY: FORMER CONFORMED NAME: Alliance Media Group Holdings, Inc. DATE OF NAME CHANGE: 20120504 10-Q 1 form10-q.htm
0001549145 false --12-31 Q2 true false 0001549145 2022-01-01 2022-06-30 0001549145 2022-08-05 0001549145 2022-06-30 0001549145 2021-12-31 0001549145 2022-04-01 2022-06-30 0001549145 2021-04-01 2021-06-30 0001549145 2021-01-01 2021-06-30 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2020-12-31 0001549145 us-gaap:PreferredStockMember 2020-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001549145 us-gaap:RetainedEarningsMember 2020-12-31 0001549145 2020-12-31 0001549145 us-gaap:CommonStockMember 2021-03-31 0001549145 us-gaap:PreferredStockMember 2021-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001549145 us-gaap:RetainedEarningsMember 2021-03-31 0001549145 2021-03-31 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001549145 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001549145 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001549145 2021-01-01 2021-03-31 0001549145 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001549145 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001549145 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 us-gaap:CommonStockMember 2021-06-30 0001549145 us-gaap:PreferredStockMember 2021-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001549145 us-gaap:RetainedEarningsMember 2021-06-30 0001549145 2021-06-30 0001549145 BIOF:IssuanceDateAprilNineteenTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-01-01 2022-06-30 0001549145 BIOF:IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-01-01 2022-06-30 0001549145 BIOF:IssuanceDateAprilNineteenTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-06-30 0001549145 BIOF:IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-06-30 0001549145 srt:MinimumMember 2022-01-01 2022-06-30 0001549145 srt:MaximumMember 2022-01-01 2022-06-30 0001549145 us-gaap:PatentsMember 2022-01-01 2022-06-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2022-01-01 2022-06-30 0001549145 2022-01-01 2022-01-02 0001549145 us-gaap:SubsequentEventMember 2022-07-01 2022-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarter ended June 30, 2022

 

Commission File Number: 000-54942

 

BLUE BIOFUELS, INC.

(Exact name of small Business Issuer as specified in its charter)

 

Nevada   45-4944960
(State or other jurisdiction   (IRS Employer
of incorporation or organization)   Identification No.)

 

3710 Buckeye Street, Suite 120    
Palm Beach Gardens, FL   33410
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 607-3555

 

n/a

 

Former name or former address if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock par value $0.001   BIOF   OTCQB

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer Emerging Growth Company
    Smaller reporting company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

 

The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was $24,775,191.

 

State the number of shares outstanding of the registrant’s $.001 par value common stock as of the close of business on the latest practicable date (August 5, 2022): 280,414,263.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I—FINANCIAL INFORMATION  
     
ITEM 1. Consolidated Financial Statements (unaudited) 4
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 22
ITEM 4. Controls and Procedures 22
     
  PART II—OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 23
ITEM 1A. Risk Factors 23
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 23
ITEM 3. Defaults Upon Senior Securities 24
ITEM 4. Mine Safety Disclosures 24
ITEM 5. Other Information 24
ITEM 6. Exhibits 24
  Signatures 25

 

2
 

 

PART I – FINANCIAL INFORMATION

 

TABLE OF CONTENTS

 

Index to Financial Statements   Page
Condensed Consolidated Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021   4
     
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)   5
     
Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)   6
     
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (unaudited)   7
     
Notes to Condensed Consolidated Financial Statements (unaudited)   8

 

3
 

 

Blue Biofuels, Inc.

Formerly known as Alliance Bioenergy Plus, Inc.

Financial Statements

Period Ended June 30, 2022

 

UNAUDITED FINANCIAL STATEMENTS

OF

BLUE BIOFUELS, INC.

 

Blue Biofuels, Inc.

CONSOLIDATED BALANCE SHEETS

(unaudited)

   June 30, 2022   December 31, 2021 
ASSETS          
Current assets          
Cash and cash equivalents  $628,906   $1,164,664 
Prepaid expenses   111,947    45,051 
TOTAL CURRENT ASSETS  $740,853   $1,209,715 
Other assets          
Property and equipment, net of accumulated depreciation and amortization of $100,189 and $273,852 at June 30, 2022 and December 31,2021, respectively.   311,334    377,645 
Security deposits   30,276    30,276 
Right of Use Assets, net of accumulated amortization   26,341    65,853 
Patents   173,030    154,758 
TOTAL OTHER ASSETS  $540,981   $628,532 
TOTAL ASSETS  $1,281,834   $1,838,247 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable  $4,000   $11,059 
Accounts payable - Related Party   72,670   $72,670 
Deferred wages and director’s fees - Related party   293,606   $240,795 
Lease Liability - Current   29,372   $72,346 
Chapter 11 Settlement   50,000    50,000 
Interest Payable - Related Party   62,714    49,291 
TOTAL CURRENT LIABILITIES  $512,362   $496,161 
Long term liabilities          
Notes Payable — Related Party   2,521,562    2,521,562 
Notes Payable — Other   216,570    216,570 
TOTAL LONG TERM LIABILITIES  $2,738,132   $2,738,132 
TOTAL LIABILITIES  $3,250,494   $3,234,293 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding   -    - 
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 279,380,263 issued and outstanding at June 30, 2022, and 274,003,883 shares issued and outstanding at December 31, 2021.   279,381    274,004 
Additional paid-in capital   49,339,709    47,151,353 
Accumulated deficit   (51,587,750)   (48,821,403)
Total stockholders’ equity (deficit)  $(1,968,660)  $(1,396,046)
TOTAL EQUITY (DEFICIT)  $(1,968,660)  $(1,396,046)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,281,834   $1,838,247 

 

4
 

 

Blue Biofuels, Inc

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

 

                     
   Three Months Ended   Six Months Ended 
   30-Jun   30-Jun 
   2022   2021   2022   2021 
Revenues  $-   $-   $-   $- 
Operating expense:                    
General and administrative   241,507    293,371    1,044,571    599,648 
Research & Development   436,480    249,786    1,666,632    514,860 
Loss on disposal of assets   40,099    -    40,099    33,484 
Total operating expenses   718,086    543,157    2,751,302    1,147,992 
                     
Loss from operations:   (718,086)   (543,157)   (2,751,302)   (1,147,992)
                     
Other (income) expense:                    
Loan Forgiveness   -    (66,330)   -    (66,330)
Interest expense - related party   6,712    6,812    13,424    13,661 
Interest expense - other   592    1,896    1,621    3,796 
Total other (income) expense   7,304    (57,622)   15,045    (48,873)
                     
Income (Loss) before provisions for income taxes  $(725,390)  $(485,535)  $(2,766,347)  $(1,099,119)
Provisions for income taxes   -    -           
Net Income / (Loss):  $(725,390)  $(485,535)  $(2,766,347)  $(1,099,119)
                     
Net income (loss) per share  $(0.003)  $(0.002)  $(0.010)  $(0.004)
                     
Weighted average common shares outstanding                    
Basic   275,876,745    266,513,255    275,876,745    266,513,255 

 

5
 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
   Common Stock   Preferred Stock   Additional Paid-in   Accumulated   Total Stockholder’s 
   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
Balance as of December 31, 2021   274,003,883   $274,004    -    -   $47,151,353   $(48,821,403)  $(1,396,046)
Issuance of common stock for services   447,781   $448    -    -   $70,852    -   $71,300 
Employee stock options exercised   150,000   $150    -    -   $7,350    -   $7,500 
Vesting of 10,560,000 options under the employee, director plan             -    -   $1,316,277    -   $1,316,277 
Net Income (Loss)                            (2,040,957)  $(2,040,957)
Balance as of March 31, 2022   274,601,664   $274,602    -    -   $48,545,832   $(50,862,360)  $(2,041,926)
Issuance of common stock for services   78,600   $79    -    -   $16,071    -   $16,150 
Employee stock options exercised   200,000    200    -    -    8,200    -    8,400 
Vesting of 800,000 options under the employee, director plan             -    -    99,106    -    99,106 
Issuance of common stock and warrants for cash through PPM   4,499,999    4,500    -    -    670,500    -    675,000 
Net Income (Loss)             -               (725,390)   (725,390)
Balance as of June 30, 2022   279,380,263   $279,381    -    -   $49,339,709   $(51,587,750)  $(1,968,660)
                                    
Balance as of December 31, 2020   241,721,947   $241,722    -    -   $43,103,607   $(46,682,093)  $(3,336,764)
Issuance of common stock for services   223,000   $223    -    -   $46,707    -   $46,930 
Issuance of 1,166,667 warrants for services        -    -    -    72,090    -    72,090 
Warrants exercised   13,455,009    13,455    -    -    1,289,362    -    1,302,817 
Issuance of common stock and warrants for cash through PPM   9,243,331    9,243    -    -    1,926,507    -    1,935,750 
Issuance of common stock in exchange for debt   7,080,000    7,080    -    -    271,920    -    279,000 
Issuance of 10,000 vested options under the employee, director plan        -              1,215         1,215 
Employee stock options exercised   350,000    350    -    -    12,550    -    12,900 
Cashless exercise of stock options   177,778    178    -    -    (178)   -    (0)
Net Income (Loss)             -               (613,584)  $(613,584)
Balance as of March 31, 2021   272,251,065   $272,251    -    -   $46,723,780   $(47,295,677)  $(299,646)
Issuance of common stock and warrants for cash through PPM   60,000   $60             $14,940        $15,000 
Issuance of 200,000 vested options under the employee, director plan                      $11,443        $11,443 
Net Income (Loss)             -     -          (485,535)  $(485,535)
Balance as of June 30, 2021   272,311,065   $272,311    -    -   $46,750,163   $(47,781,212)  $(758,738)

 

6
 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

   30-Jun-22   30-Jun-21 
   For the Six Months Ended   For the Six Months Ended 
   30-Jun-22   30-Jun-21 
Cash flows from operating activities          
Net Income (Loss)  $(2,766,347)  $(1,099,119)
Reconciliation of net loss to net cash used in operating activities          
Depreciation and amortization   68,123    63,001 
Stock based compensation for services   87,450    46,930 
Net Issuance of options and warrants for services   1,415,383    84,748 
Loss on Disposal of assets   40,099    33,484 
Changes in operating assets and liabilities          
Prepaid expenses   (66,896)   (33,091)
Accrued interest - related party   13,424    (42,400)
Accounts payable and accrued liabilities   45,753    (508,768)
Forgiveness of PPP Loan   -    (66,330)
Right of use lease   (42,974)   (39,227)
Net cash used in operating activities   (1,205,985)   (1,560,772)
           
Cash flows from investing activities          
Purchase of property and equipment   (2,400)   (114,673)
Patent Costs   (18,273)   (14,504)
Net cash from (used in) investing activities   (20,673)   (129,177)
           
Cash flows from financing activities          
Proceeds from exercise of warrants and options   15,900    1,315,717 
Net proceeds from issuance of common stock   675,000    1,950,750 
Net cash provided by financing activities   690,900    3,266,467 
           
Net increase (decrease) in cash and cash equivalents   (535,758)   1,576,518 
           
Cash and cash equivalent at beginning of the period   1,164,664    286,579 
Cash and cash equivalent at end of the period  $628,906   $1,863,097 
           
Supplemental disclosure of cash flow information          
Cash paid during the period for          
Interest  $-   $- 
Taxes  $-   $- 
           
Supplemental schedule of non-cash activities          
Cashless conversion of warrants/options  $-   $- 
Conversion of convertible debenture to common stock  $-   $279,000 

 

7
 

 

Blue Biofuels, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin. In early 2018, the Company’s Chief Executive Officer (“CEO”) Ben Slager invented a new technology system we call Cellulose-to-Sugar or CTS, and the Company filed a patent application for this technology. The CTS patent was awarded in 2021 in the United States (US10994255) and also in El Salvador. The Company also filed an application for this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. The Company has filed six more patents in the United States, all of which are currently pending. These patents broaden the scope and protection of the CTS technology.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin, as compared to the prior process which was a batch mechanical/chemical dry process previously used by our Company. The CTS creates molecular contact between two reactive solid components instead of a more conventional reaction where the reaction takes place between two liquid or gas components in a batch process. The reactants are (1) the cellulose, which is broken down into its components being sugars and lignin; (2) a catalyst, which is cost effective and abundantly available in the market from regular suppliers; it is recycled and reused in the process. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS differs from other commercial processes that are used to convert cellulose into sugar. Other processes use expensive enzymes, or expensive and harmful chemicals like strong acids or bases. Some use high temperature or high pressure steam. CTS can convert cellulosic material – including grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or king grass, and the cellulosic portion of municipal solid waste – into sugars and lignin, and the sugars subsequently into biofuels in a what is expected to be a cost effective and environmentally friendly way. The process times needed are significantly shorter than any other cellulosic process. CTS has a near zero carbon footprint in that the amount of added atmospheric carbon created by burning the biofuels produced by CTS is reabsorbed by the plant-based seed stock used in the CTS system. The CTS process recycles the water and catalyst.

 

At a commercial scale, our management expects to be able to produce ethanol more profitably than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process has much lower feedstock cost than corn, is uncomplicated and efficient as compared to other cellulosic ethanol processes, and is expected to have high value by-products and a highly valued D3 RIN that the Company expects to potentially receive for each gallon of ethanol. The Company believes a significant difference between CTS and corn ethanol is the wide range of feedstocks that CTS can process compared to corn. The CTS feedstocks are not food and have much lower costs than corn. In addition, while in corn ethanol only the corn is used, the CTS uses the whole plant or its waste products.

 

The new CTS technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

The Company has built several prototypes of the CTS system to solidify and further develop the process. The Company completed all the parameter optimizations possible in its lab and was able to generate a 99%+ conversion of the cellulosic material into soluble sugars suitable for further processing into cellulosic ethanol. The Company has recently contracted with K.R. Komarek to build larger scale systems, the first of which is anticipated to arrive before the end of the summer of 2022.

 

The goal of the first Komarek system is to process much larger volumes of feedstock to produce much higher volumes of sugars. Upon success, the Company anticipates ordering a larger system and building a semi-commercial scale pilot CTS plant around that. This will be an intermediate step to the final commercial-scale system. The Company believes that the semi-commercial scale plant will be sufficient to prove the commercial viability of the CTS technology. Due to its mechanical nature and modularity, management anticipates that one commercial-scale CTS plant would have multiple modular CTS systems. The Company expects to have the pilot plant running in 2023.

 

The CTS system converts plant-based feedstock into two product streams, cellulose and lignin, each of which can be converted into multiple products: (1) Cellulose is broken down into sugars. Sugar can be used to make biofuels, such as ethanol and sustainable aviation fuel, and may also be used to make specialty chemicals; and (2) Lignin can potentially be used in ion exchange resins, or to make specialty chemicals; It can also be burned as a renewable fuel.

 

8
 

 

Plan of Operation

 

The Company’s strategy is to diversify its product portfolio to include a number of product lines. These potentially include (1) biofuels – such as ethanol, or converting ethanol into higher biofuels like sustainable aviation fuel and the like; (2) selling sulfur-free lignin to ion exchange resin producers; (3) making specialty chemicals from lignin; and, (4) potentially making nanocellulose. We believe these, and other markets, could potentially provide for highly profitable products.

 

Our goal is to develop our CTS technology to a commercial scale and then seek to either enter into a joint venture or acquire existing corn ethanol plants to install the CTS technology. The Company is also looking into converting ethanol to sustainable aviation fuel. To minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin and other specialty chemicals from its patented CTS system.

 

Management believes that retrofitting existing plants with the CTS technology may achieve more rapid commercialization than building new plants. After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we expect that our profitability will potentially be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (“EPA”), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

The Company has also licensed the Vertimass Process to convert ethanol (from the CTS process) into sustainable aviation fuel. There is no up-front or annual fee until we are converting ethanol into SAF. The license agreement with Vertimass is the subject of a confidentiality agreement between the parties. Since we are not yet producing ethanol on a commercial scale, it is too preliminary to discuss details.

 

9
 

 

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2022, the Company has incurred accumulated losses of $51,587,750. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our customers, employees and supply chain. Given the critical nature of the products that we provide, our office and lab have remained open during the pandemic. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

10
 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:

 

   4/19/22   6/21/22 
Risk-free interest rate   2.93%   3.38%
Expected life   10 years    5 years 
Expected dividends   0%   0%
Expected volatility   133.42%   134.52%
BIOF common stock fair value  $0.165   $0.167 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $173,030 as of June 30, 2022 and $154,758 as of December 31, 2021.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2022, and June 30, 2021, the amounts charged to research and development expenses were $1,666,632, and $514,860, respectively.

 

Revenue Recognition

 

Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09:

 

  1. Identify contract(s) with a customer;
  2.

Identify the performance obligations in the contract;

  3. Determine the transaction price;
  4.

Allocate the transaction price to the performance obligations in the contract; and,

  5.

Recognize revenues when (or as) we satisfy the performance obligation.

 

11
 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

12
 

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

NOTE 4 – PATENTS

 

The Company has been granted one patent on its technology, has filed for six others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $173,030 as of June 30, 2022.

 

NOTE 5 – DEBT

 

Notes Payable – Chapter 11 Settlement

 

On July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $2,694,577 dollars plus stock warrants in the Circuit Court of the 15th Judicial Circuit in Palm Beach County, Florida. That lawsuit was moved to the Bankruptcy Court when the Company entered Chapter 11 on October 22, 2018. The Company filed a Complaint against Lenaburg on November 16, 2018, in the bankruptcy court in the Southern District of Florida. The bankruptcy judge ordered mediation, and a settlement was reached that paid Lenaburg $13,650 upon Plan Confirmation and a $50,000 claim payable out of post-confirmation net profits over 3 years, plus 1.5 million common stock warrants with a strike price of $0.30/share and a ten-year expiration period. The $50,000 is due on September 18, 2022.

 

Notes Payable – Related Parties

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the notes was $278,794.68 and $176,460 respectively. All of the notes were due on August 4, 2017 and then were in default. However, the notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company, or, at its option, may convert that into an equity investment in the first plant of the Company, measured by a percentage of the total cost to build, subject to a minimum equity interest of 1.25% in said plant.

 

13
 

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000 and are being amortized over the life of the note. The note’s maturity date was extended to 7/1/2018. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full, with no additional shares to be issued.

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the note was $14,382.2 and $8,588 respectively. The note was due on August 4, 2017 and was then in default. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018 and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

14
 

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500, and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30,

2022

  

December 31,

2021

 
Short Term Chapter 11 Settlement  $50,000   $50,000 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $2,788,132   $2,788,132 

 

Of the $2,788,132 due as of June 30, 2022, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $370,630, consisting of $200,630 due to related parties, $120,000 due to other, and a $50,000 Chapter 11 settlement.

 

NOTE 6 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of June 30, 2022, the Company had 279,380,263 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the six months ended June 30, 2022, the Company issued an aggregate of 526,381 shares of its common stock for services valued at $87,450.

 

For the six months ended June 30, 2022, the Company issued an aggregate of 4,499,999 shares of its common stock for cash valued at $675,000.

 

For the six months ended June 30, 2022, 350,000 employee stock options were exercised for proceeds of $15,900.

 

For the six months ended June 30, 2022, 687,500 warrants expired.

 

For the six months ended June 30, 2022, 2,604,466 options expired.

 

For the six months ended June 30, 2022, 11,360,000 stock options vested.

 

15
 

 

NOTE 7 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.

 

On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believed the Complaint was frivolous. On June 28, 2022, Power Up Lending Group withdrew the case, and there was no financial cost to the Company or its Management team.

 

Leases

 

The Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022. Annual rent commenced at $84,100 per annum and increases 3% per year. Tenant is also required to cover operating costs that, as of January 1, 2022, are estimated at $3,379 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

Rent expense for the six months ending June 30, 2022, and 2021, were $64,724 and $63,921, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30,

2022

  

December 31,

2021

 
Right of Use Lease Liabilities          
Current portion   29,372    72,346 
Long-term portion   0    0 
TOTAL   29,372    72,346 

 

As of June 30, 2022, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2022   29,372 
2023   0 
2024   0 
      
TOTAL  $29,372 

 

16
 

 

NOTE 8 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 5.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 

NOTE 9 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From June 30, 2022, to the date of this filing, the Company issued 34,000 shares for services.

 

From June 30, 2022, to the date of this filing, 150,000 warrants expired.

 

From June 30, 2022, to the date of this filing, 25,000 previously issued options vested.

 

From June 30, 2022, to the date of this filing, the Company issued 1,000,000 shares in a private placement for proceeds of $150,000.

 

17
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

The following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto.

 

Forward-Looking Statements

 

This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

 

Business Overview

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin. In early 2018, the Company’s Chief Executive Officer (“CEO”) Ben Slager invented a new technology system we call Cellulose-to-Sugar or CTS, and the Company filed a patent application for this technology. The CTS patent was awarded in 2021 in the United States (US10994255) and also in El Salvador. The Company also filed an application for this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. The Company has filed six more patents in the United States, all of which are currently pending. These patents pertain to the CTS process, the “fingerprint” of our sugars coming from the process, and the lignin and nanocellulose coming from the process.

 

Mr. Slager has since further developed the system with laboratory personnel. The patented CTS process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin, as compared to the prior process which was a batch mechanical/chemical dry process previously used by our Company. The CTS creates molecular contact between two reactive solid components instead of a more conventional reaction where the reaction takes place between two liquid or gas components in a batch process. The reactants are (1) the cellulose, which is broken down into its components being sugars and lignin; (2) a catalyst, which is cheap and abundantly available in the market from regular suppliers, and separated from reactor components and reused. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS differs from other commercial processes that are used to convert cellulose into sugar. Other processes use expensive enzymes, or expensive and harmful chemicals like strong acids or bases. Some use high temperature or high pressure steam. CTS can convert any cellulosic material – including grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or king grass, and the cellulosic portion of municipal solid waste – into sugars and lignin, and the sugars subsequently into biofuels without the use of expensive enzymes or harmful liquid acids or bases. CTS has a near zero carbon footprint in that the amount of added atmospheric carbon created by burning the biofuels produced by CTS is reabsorbed by the plant-based seed stock used in the CTS system, and recycles the water and catalyst.

 

At a commercial scale, our management expects to be able to produce ethanol more profitably per gallon than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process is uncomplicated and efficient, and is expected to have high value by-products and a highly valued D3 RIN that the Company expects to potentially receive for each gallon of ethanol. We believe a significant difference between CTS and corn ethanol is the wide range of feedstocks that CTS can process compared to corn. The CTS feedstocks are not food and have much lower costs than corn. In addition, while in corn ethanol only the corn is used, the CTS uses the whole plant or its waste products.

 

18
 

 

The Company has built several prototypes of the CTS system to solidify and further develop the process. The Company completed all the parameter optimizations possible in its lab and was able to generate a 99%+ conversion of the cellulosic material into soluble sugars suitable for further processing into cellulosic ethanol. The Company has recently contracted with K.R. Komarek to build larger scale systems, the first of which is anticipated to arrive before the end of the summer of 2022.

 

The goal of the first Komarek system is to provide larger volume production of sugars. Upon success, the Company anticipates ordering a larger system and building a semi-commercial scale pilot CTS plant around that. This will be an intermediate step to the final commercial-scale system. The Company believes that the semi-commercial scale plant will be sufficient to prove the commercial viability of the CTS technology. Due to its mechanical nature and modularity, management anticipates that one commercial-scale CTS plant would have multiple modular CTS systems. The Company expects to have the pilot plant running in 2023.

 

The CTS system converts plant-based feedstock into two product streams, cellulose and lignin, each of which can be converted into multiple products: (1) Cellulose is broken down into sugars. Sugar can be used to make biofuels, such as ethanol and sustainable aviation fuel, and may also be used to make specialty chemicals; and (2) Lignin can potentially be used in ion exchange resins, or to make specialty chemicals; It can also be burned as a renewable fuel.

 

Plan of Operation

 

The Company’s strategy is to diversify its product portfolio to include a number of product lines. These potentially include (1) biofuels – such as ethanol, or converting ethanol into higher biofuels like sustainable aviation fuel and the like; (2) selling sulfur-free lignin to ion exchange resin producers; (3) making specialty chemicals from lignin; and, (4) making nanocellulose. We believe these, and other markets, could potentially provide for highly profitable products.

 

Our goal is to develop our CTS technology to a commercial scale and then seek to either enter into a joint venture or acquire existing corn ethanol plants to install the CTS technology. The Company is also looking into converting ethanol to sustainable aviation fuel. To minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin and other specialty chemicals from its patented CTS system.

 

Management believes that retrofitting existing plants with the CTS technology may achieve more rapid commercialization than building new plants. After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

The ethanol industry is highly competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we expect that our profitability will potentially be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing. The Company would also need various government permits before commercializing products for the plastics industry.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (“EPA”), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s newly proposed revised mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

The Company has also licensed the Vertimass Process to convert ethanol (from the CTS process) into sustainable aviation fuel. There is no up-front or annual fee until we are converting ethanol into SAF. The license agreement with Vertimass is the subject of a confidentiality agreement between the parties. Since we are not yet producing ethanol on a commercial scale, it is too preliminary to discuss details.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has generated $194,319 in revenue, however it has not generated any revenues from its core business.

 

19
 

 

Capital Formation

 

From January 1, 2022, through the date of filing, the Company issued an aggregate of 560,381 shares of its common stock for services valued at $92,550.

 

On April 29, 2022, the Company commenced a new offering of shares of its common stock valued at $0.15 per share. Through the date of filing, the Company has sold an aggregate of 5,499,999 shares of its common stock for capital of $825,000.

 

From January 1, 2022, through the date of filing, the Company issued unvested options to its managers and employees to purchase 2,000,000 shares of its common stock for a period between five and ten years at the exercise price of 17 cents per share. Using a Black-Scholes asset-pricing model, these agreements were valued at $319,327. None of those have vested, but 11,385,000 other options have vested, with a valuation of $1,420,404.

 

From January 1, 2022, through the date of filing, 2,604,466 options expired and 837,500 warrants expired.

 

From January 1, 2022, through the date of filing, 350,000 previously issued options were exercised for proceeds of $15,900.

 

Going Concern

 

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. At June 30, 2022, the Company had a working capital surplus of $228,491 and had incurred accumulated losses of $51,587,750 since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is substantial doubt about the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses.

 

Results of Operations

 

Comparison of the three and six month period ended June 30, 2022 (unaudited) to June 30, 2021

 

For the three and six months ended June 30, 2022, the Company recognized $0 in revenue as opposed to $0 in 2021.

 

For the three months ended June 30, 2022, the Company’s general and administrative expenses decreased by $51,864 to $241,507 from $293,371 in 2021. This decrease is primarily the result of a $69,791 decrease in professional fees to 30,830 in 2022 from $100,621 in 2021, primarily related to accounting and legal work bringing the company current again in its financial reporting in 2021.

 

For the six months ended June 30, 2022, the Company’s general and administrative expenses increased by $444,923 to $1,044,571 from $599,648 in 2021. This increase is primarily the result of a $495,532 increase in equity-based compensation from $11,443 in 2021.

 

Interest expense decreased in the quarter ended June 30, 2022 by $1,403 to $7,304 from $8,708 in 2021. Interest expense decreased in the six months ended June 30, 2022 by $2,412 to $15,045 from $17,457 in 2021.

 

For the six months ended June 30, 2022 the Company recorded non-cash impairments of assets of $40,099, as compared to $33,484 in 2021. This was the result of disposing and/or selling of laboratory assets no longer in use in each year.

 

Research and development (R&D) costs for the quarter ended June 30, 2022 were $436,480, an increase of $186,694 from $249,786 in 2021. The increase in R&D expenses is primarily the result of an increase in payroll of $54,461 from the hiring of additional personnel, and $99,106 in equity-based compensation from $0 in 2021 due to the vesting of options in 2022.

 

Research and development (R&D) costs for the six months ended June 30, 2022 were $1,666,632, an increase of $1,151,772 from $514,860 in 2021. The increase in R&D expenses is primarily the result of an increase in payroll of $158,748 from the hiring of additional personnel, and $919,851 in equity-based compensation from $0 in 2021 due to the vesting of options in 2022.

 

20
 

 

Liquidity and Capital Resources

 

Liquidity

 

As of June 30, 2022, the Company had $628,906 in cash, and total stockholders’ equity on June 30, 2022, was negative $1,968,660. As of December 31, 2021, the Company had $1,164,664 in cash, and total stockholders’ equity at December 31, 2021, was negative $1,396,046. Total debt, including advances, accounts payable and other notes payable at June 30, 2022, together with interest payable thereon and contingent liabilities, was $3,250,494 an increase of $16,202 from December 31, 2021, where it stood at $3,234,293. This increase is attributable to the increases in deferred wages due to management. $1,820,630 of the remaining debt has been renegotiated to be payable out of future revenue and $917,502 out of future profits and otherwise does not come due.

 

During the six months ended June 30, 2022, the Company’s net cash used in operating activities decreased by $354,787 to $1,205,985 from $1,560,772 in the six months ending June 30, 2021. This decrease can primarily be attributed to an increase in accounts payable of $45,753 in 2022, versus a reduction in accounts payable of $508,768 in 2021 attributed to paying off back-pay due.

 

During the six months ended June 30, 2022, the Company’s investing activities used $20,673 in cash. This can be primarily attributed to capitalizing $18,273 in patent costs and $2,400 used to purchase machinery and equipment. During the six months ended June 30, 2021, the Company’s investing activities used $129,177. This is primarily due to the purchase of equipment of $114,673 and $14,504 in patent costs.

 

During the six months ended June 30, 2022, the Company generated an aggregate of $690,900 through its financing activities, which is a decrease of $2,575,567 from $3,266,467 during the six months ended June 30, 2021. This decrease from the prior year can primarily be attributed to the lack of an equity raise in the first quarter of 2022 and only the start of one in its second quarter raising $675,000, as compared to $1,950,750 raised from the sale of common stock through the Company’s private offerings in 2021, and $1,315,717 in proceeds from the exercise of warrants and options.

 

Capital Resources

 

At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional financing for current and future operations. The Company anticipates needing around $7.5 to $10 million to scale up its CTS system to be commercially ready. The Company anticipates reaching this stage around 12 months. There is no guarantee that we will achieve all of the additional funding that is needed.

 

As of the date of this filing, the Company has raised $765,900 in 2022, through the sale of stock and the exercise of options, in addition to $14,574,702 previously raised, in addition to capital raised through debt or convertible notes. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company.

 

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

 

Equity

 

As of June 30, 2022, shareholders’ equity was negative $1,968,660.

 

There were 279,380,263 shares of common stock issued and outstanding as of June 30, 2022.

 

There were no preferred shares outstanding.

 

The Company has paid no dividends.

 

Critical Accounting Policies

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

21
 

 

Seasonality

 

The Company’s operating results are not affected by seasonality.

 

Inflation

 

The Company’s business and operating results are not affected in any material way by inflation.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of December 31, 2021. Based upon, and as of the date of this evaluation, our chief executive officer and chief financial officer determined that our disclosure controls and procedures were sufficient.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of December 31, 2021, that occurred during our first fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

22
 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.

 

On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&O insurance has agreed to cover the legal defense costs for CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believed the Complaint was frivolous. On June 28, 2022, Power Up Lending Group withdrew the lawsuit against management. The case is now closed. There has been no financial cost to the Company or its Management team.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

 

Below is a list of securities sold by the Company from January 1, 2022, through the date of filing which were not registered under the Securities Act.

 

Entity  

Date of

Investment

 

Title of

Security

   

Amount of

Securities

Sold

    Consideration
Tom Camerlengo   01/11/22   Common Stock     150,000     Exercise of Options
North Equities   03/05/22   Common Stock      322,581     Professional Services
Bill Fitzpatrick   03/10/22   Common Stock      100,000     Professional Services
NWBB, Inc   03/10/22   Common Stock      25,200     Professional Services
NWBB, Inc   04/22/22   Common Stock     28,600     Professional Services
Ben Slager   04/29/22   Common Stock     500,000     Purchase @ $0.15 per share
AES Capital Resource Fund   05/02/22   Common Stock     500,000     Purchase @ $0.15 per share
Chris and Angela Kneppers   05/02/22   Common Stock     2,333,333     Purchase @ $0.15 per share
Raymond Leon   05/04/22   Common Stock     500,000     Purchase @ $0.15 per share
Melvin H. Eaton II   05/23/22   Common Stock     333,333     Purchase @ $0.15 per share
Mark Monahan   05/23/22   Common Stock     333,333     Purchase @ $0.15 per share
Johan Foster   05/26/22   Common Stock     25,000     Professional Services
Caroline Libra   05/26/22   Common Stock     25,000     Professional Services
Thomas Camerlengo   05/31/22   Common Stock     200,000     Exercise of Options
Steve Paul   07/07/22   Common Stock     166,667     Purchase @ $0.15 per share
Randall Brodsky   07/11/22   Common Stock     333,333     Purchase @ $0.15 per share
NWBB, Inc.   07/12/22   Common Stock     34,000     Professional Services
Mudai Nakagawa   07/22/22   Common Stock     500,000     Purchase @ $0.15 per share

 

The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504 and 506 of Regulation D.

 

23
 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

The exhibits listed below are filed as part of or incorporated by reference in this report.

 

Exhibit No.   Identification of Exhibit
     
2.1   Chapter 11 Plan of Reorganization (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
2.2   Chapter 11 Disclosure Statement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.1   Articles of Incorporation (incorporated by reference to the Company’s S-1 filed May 23, 2021)
     
3.2   Certificate of Amendment to Articles of Incorporation filed November 19, 2014 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.3   Certificate of Amendment to Articles of Incorporation filed June 17, 2016 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.4   Certificate of Amendment to Articles of Incorporation filed July 26, 2021 (incorporated by reference to the Company’s 8-K filed on July 30, 2021)
     
3.5   Bylaws (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.1   Lease Agreement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.2   Employment Agreement, dated June 1, 2020, between the Company and Ben Slager (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.3   Employment Agreement, dated June 1, 2020, between the Company and Anthony Santelli (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021
     
10.4   2021 Employee, Director Stock Plan (incorporated by reference to definitive 14C filed with the SEC on June 24, 2021)
     
31.1.   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

24
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Blue Biofuels, Inc.
  (Registrant)
     
  By /s/ Benjamin Slager
    Benjamin Slager
    Chief Executive Officer, (Principal Executive Officer)
     
  Date  August 8, 2022
     
  By /s/ Anthony Santelli
    Anthony Santelli
    Chief Financial Officer (Principal Financial and Accounting Officer)
     
  Date  August 8, 2022

 

25
EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Benjamin Slager, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 8, 2022

 

/s/ Benjamin Slager  
Benjamin Slager  

Chief Executive Officer

(Principal Executive Officer)

 

 

 
EX-31.2 3 ex31-2.htm

  

Exhibit 31.2

 

CERTIFICATIONS

 

I, Anthony Santelli, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
       
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 8, 2022

 

/s/ Anthony Santelli  
Anthony Santelli  

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 
EX-32.1 4 ex32-1.htm

  

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Benjamin Slager, the Chief Executive Officer of Blue Biofuels, Inc (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 8th day of August, 2022.

 

  /s/ Benjamin Slager
  Benjamin Slager
 

Chief Executive Officer

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
EX-32.2 5 ex32-2.htm

  

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Anthony Santelli, the Chief Financial Officer of Blue Biofuels, Inc. (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 8th day of August, 2022.

 

  /s/ Anthony Santelli
  Anthony Santelli
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

EX-101.SCH 6 biof-20220630.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 biof-20220630_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 biof-20220630_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 biof-20220630_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Award Date [Axis] Issuance Date April Nineteen Two Thousand Twenty Two [Member] Warrant [Member] Issuance Date June Twenty One Two Thousand Twenty Two [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Long-Lived Tangible Asset [Axis] Office and Laboratory Space [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Prepaid expenses TOTAL CURRENT ASSETS Other assets Property and equipment, net of accumulated depreciation and amortization of $100,189 and $273,852 at June 30, 2022 and December 31,2021, respectively. Security deposits Right of Use Assets, net of accumulated amortization Patents TOTAL OTHER ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable Accounts payable - Related Party Deferred wages and director’s fees - Related party Lease Liability - Current Chapter 11 Settlement Interest Payable - Related Party TOTAL CURRENT LIABILITIES Long term liabilities Notes Payable — Related Party Notes Payable — Other TOTAL LONG TERM LIABILITIES TOTAL LIABILITIES STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding Common stock; $0.001 par value; 1,000,000,000 shares authorized; 279,380,263 issued and outstanding at June 30, 2022, and 274,003,883 shares issued and outstanding at December 31, 2021. Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) TOTAL EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Accumulated depreciation and amortization on property and equipment Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating expense: General and administrative Research & Development Loss on disposal of assets Total operating expenses Loss from operations: Other (income) expense: Loan Forgiveness Interest expense - related party Interest expense - other Total other (income) expense Income (Loss) before provisions for income taxes Provisions for income taxes Net Income / (Loss): Net income (loss) per share Weighted average common shares outstanding Basic Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Issuance of common stock for services Issuance of common stock for services, shares Employee stock options exercised Employee stock options exercised, shares Issuance of vested options under the employee, director plan Net Income (Loss) Issuance of common stock and warrants for cash through PPM Issuance of common stock and warrants for cash through PPM, shares Issuance of 1,166,667 warrants for services Warrants exercised Warrants exercised, shares Issuance of common stock in exchange for debt Issuance of common stock in exchange for debt, shares Cashless exercise of stock options Cashless exercise of stock options, shares Ending balance, value Ending balance, shares Statement of Stockholders' Equity [Abstract] Vested options issued under employee director plan Warrants issued for services Statement of Cash Flows [Abstract] Cash flows from operating activities Reconciliation of net loss to net cash used in operating activities Depreciation and amortization Stock based compensation for services Net Issuance of options and warrants for services Loss on Disposal of assets Changes in operating assets and liabilities Prepaid expenses Accrued interest - related party Accounts payable and accrued liabilities Forgiveness of PPP Loan Right of use lease Net cash used in operating activities Cash flows from investing activities Purchase of property and equipment Patent Costs Net cash from (used in) investing activities Cash flows from financing activities Proceeds from exercise of warrants and options Net proceeds from issuance of common stock Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalent at beginning of the period Cash and cash equivalent at end of the period Supplemental disclosure of cash flow information Cash paid during the period for Interest Taxes Supplemental schedule of non-cash activities Cashless conversion of warrants/options Conversion of convertible debenture to common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Goodwill and Intangible Assets Disclosure [Abstract] PATENTS Debt Disclosure [Abstract] DEBT Equity [Abstract] STOCKHOLDERS’ EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Use of Estimates Cash and Cash Equivalents Stock Compensation Stock-based Compensation Valuation Methodology Property and Equipment Patent Capitalization Research and Development Revenue Recognition Common Stock Purchase Warrants and Other Derivative Financial Instruments Impairment of Long-Lived Assets Income Taxes Profit (Loss) per Common Share Fair Value Measurements Recent Accounting Pronouncements SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION SCHEDULE OF NOTES PAYABLE SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Renewable fuel description Accumulated losses Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-free interest rate Expected life Expected dividends Expected volatility BIOF common stock fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, estimated useful life Research and Development Expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Legal and filing fees Short Term Chapter 11 Settlement Long Term Notes Payable from future revenue — Related Party Long Term Notes Payable from future revenue — Other Long Term Note Payable from future profits — Related Party Long Term Note Payable from future profits — Other TOTAL NOTES Capital units, authorized Preferred stock, shares Issued Number of shares issued for services, shares Number of shares issued for services Employee stock options exercised, shares Employee stock options exercised Number of warrants expired Stock options expired Stock options vested Current portion Long-term portion TOTAL 2022 2023 2024 TOTAL Lease description Lease extension period Annual rent Percentage of increase in rent per year Operating costs Rent expense Subsequent Event [Table] Subsequent Event [Line Items] Number of shares issued for private placement Proceeds from issuance of private placement Stockholders Equity Deficit. Stock issued during period value stock options exercised 1. Stock issued during period shares stock options exercised 1. Warrants issued for service. Issuance of common stock and warrants for cash through Ppm. Issuance of Common Stock and Warrants for Cash Through PPM Shares. Increase decrease in right of use lease. Payments for patent costs. Cashless conversion of warrants. Conversion of convertible debenture to common stock. Loan forgiveness. Renewable Fuel Description. Stockbased Compensation Valuation Methodology [Policy Text Block] Issuance Date April Nineteen Two Thousand Twenty Two [Member] Issuance Date June Twenty One Two Thousand Twenty Two [Member] Common Stock Purchase Warrants And Other Derivative Financial Instruments [Policy Text Block] Office and Laboratory Space [Member] Percentage of increase in rent per year. Long term notes payable from future revenue related party. Long Term Notes Payable From Future Revenue Other. Long term note payable from future profits related party. Long term note payable from future profits other. Increase decrease in forgiveness of loan. Warrants exercised. Warrants exercised, shares. Stock options vested. Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent StockholdersEquityDeficit Liabilities and Equity Gain (Loss) on Disposition of Assets Operating Expenses Operating Income (Loss) LoanForgiveness Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Prepaid Expense IncreaseDecreaseInForgivenessOfLoan Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsForPatentCosts Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Notes Payable Operating Lease, Liability Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 10 biof-20220630_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
6 Months Ended
Jun. 30, 2022
Aug. 05, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-54942  
Entity Registrant Name BLUE BIOFUELS, INC.  
Entity Central Index Key 0001549145  
Entity Tax Identification Number 45-4944960  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 3710 Buckeye Street  
Entity Address, Address Line Two Suite 120  
Entity Address, City or Town Palm Beach Gardens  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33410  
City Area Code 888  
Local Phone Number 607-3555  
Trading Symbol BIOF  
Title of 12(g) Security Common Stock par value $0.001  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   280,414,263
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 628,906 $ 1,164,664
Prepaid expenses 111,947 45,051
TOTAL CURRENT ASSETS 740,853 1,209,715
Other assets    
Property and equipment, net of accumulated depreciation and amortization of $100,189 and $273,852 at June 30, 2022 and December 31,2021, respectively. 311,334 377,645
Security deposits 30,276 30,276
Right of Use Assets, net of accumulated amortization 26,341 65,853
Patents 173,030 154,758
TOTAL OTHER ASSETS 540,981 628,532
TOTAL ASSETS 1,281,834 1,838,247
Current liabilities    
Accounts payable 4,000 11,059
Accounts payable - Related Party 72,670 72,670
Deferred wages and director’s fees - Related party 293,606 240,795
Lease Liability - Current 29,372 72,346
Chapter 11 Settlement 50,000 50,000
Interest Payable - Related Party 62,714 49,291
TOTAL CURRENT LIABILITIES 512,362 496,161
Long term liabilities    
Notes Payable — Related Party 2,521,562 2,521,562
Notes Payable — Other 216,570 216,570
TOTAL LONG TERM LIABILITIES 2,738,132 2,738,132
TOTAL LIABILITIES 3,250,494 3,234,293
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 279,380,263 issued and outstanding at June 30, 2022, and 274,003,883 shares issued and outstanding at December 31, 2021. 279,381 274,004
Additional paid-in capital 49,339,709 47,151,353
Accumulated deficit (51,587,750) (48,821,403)
Total stockholders’ equity (deficit) (1,968,660) (1,396,046)
TOTAL EQUITY (DEFICIT) (1,968,660) (1,396,046)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,281,834 $ 1,838,247
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Accumulated depreciation and amortization on property and equipment $ 100,189 $ 273,852
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 279,380,263 274,003,883
Common stock, shares outstanding 279,380,263 274,003,883
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statement of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenues
Operating expense:        
General and administrative 241,507 293,371 1,044,571 599,648
Research & Development 436,480 249,786 1,666,632 514,860
Loss on disposal of assets 40,099 40,099 33,484
Total operating expenses 718,086 543,157 2,751,302 1,147,992
Loss from operations: (718,086) (543,157) (2,751,302) (1,147,992)
Other (income) expense:        
Loan Forgiveness (66,330) (66,330)
Interest expense - related party 6,712 6,812 13,424 13,661
Interest expense - other 592 1,896 1,621 3,796
Total other (income) expense 7,304 (57,622) 15,045 (48,873)
Income (Loss) before provisions for income taxes (725,390) (485,535) (2,766,347) (1,099,119)
Provisions for income taxes    
Net Income / (Loss): $ (725,390) $ (485,535) $ (2,766,347) $ (1,099,119)
Net income (loss) per share $ (0.003) $ (0.002) $ (0.010) $ (0.004)
Weighted average common shares outstanding        
Basic 275,876,745 266,513,255 275,876,745 266,513,255
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 241,722 $ 43,103,607 $ (46,682,093) $ (3,336,764)
Beginning balance, shares at Dec. 31, 2020 241,721,947      
Issuance of common stock for services $ 223 46,707 46,930
Issuance of common stock for services, shares 223,000        
Employee stock options exercised $ 350 12,550 12,900
Employee stock options exercised, shares 350,000        
Issuance of vested options under the employee, director plan   1,215   1,215
Net Income (Loss)       (613,584) (613,584)
Issuance of common stock and warrants for cash through PPM $ 9,243 1,926,507 1,935,750
Issuance of common stock and warrants for cash through PPM, shares 9,243,331        
Issuance of 1,166,667 warrants for services 72,090 72,090
Warrants exercised $ 13,455 1,289,362 1,302,817
Warrants exercised, shares 13,455,009        
Issuance of common stock in exchange for debt $ 7,080 271,920 279,000
Issuance of common stock in exchange for debt, shares 7,080,000        
Cashless exercise of stock options $ 178 (178) (0)
Cashless exercise of stock options, shares 177,778        
Ending balance, value at Mar. 31, 2021 $ 272,251 46,723,780 (47,295,677) (299,646)
Ending balance, shares at Mar. 31, 2021 272,251,065      
Beginning balance, value at Dec. 31, 2020 $ 241,722 43,103,607 (46,682,093) (3,336,764)
Beginning balance, shares at Dec. 31, 2020 241,721,947      
Net Income (Loss)         (1,099,119)
Ending balance, value at Jun. 30, 2021 $ 272,311 46,750,163 (47,781,212) (758,738)
Ending balance, shares at Jun. 30, 2021 272,311,065      
Beginning balance, value at Mar. 31, 2021 $ 272,251 46,723,780 (47,295,677) (299,646)
Beginning balance, shares at Mar. 31, 2021 272,251,065      
Issuance of vested options under the employee, director plan     11,443   11,443
Net Income (Loss)     (485,535) (485,535)
Issuance of common stock and warrants for cash through PPM $ 60   14,940   15,000
Issuance of common stock and warrants for cash through PPM, shares 60,000        
Ending balance, value at Jun. 30, 2021 $ 272,311 46,750,163 (47,781,212) (758,738)
Ending balance, shares at Jun. 30, 2021 272,311,065      
Beginning balance, value at Dec. 31, 2021 $ 274,004 47,151,353 (48,821,403) (1,396,046)
Beginning balance, shares at Dec. 31, 2021 274,003,883      
Issuance of common stock for services $ 448 70,852 71,300
Issuance of common stock for services, shares 447,781        
Employee stock options exercised $ 150 7,350 7,500
Employee stock options exercised, shares 150,000        
Issuance of vested options under the employee, director plan   1,316,277 1,316,277
Net Income (Loss)       (2,040,957) (2,040,957)
Ending balance, value at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Ending balance, shares at Mar. 31, 2022 274,601,664      
Beginning balance, value at Dec. 31, 2021 $ 274,004 47,151,353 (48,821,403) (1,396,046)
Beginning balance, shares at Dec. 31, 2021 274,003,883      
Issuance of common stock for services         $ 87,450
Issuance of common stock for services, shares         526,381
Net Income (Loss)         $ (2,766,347)
Issuance of common stock and warrants for cash through PPM         $ 675,000
Issuance of common stock and warrants for cash through PPM, shares         4,499,999
Cashless exercise of stock options         $ 15,900
Cashless exercise of stock options, shares         350,000
Ending balance, value at Jun. 30, 2022 $ 279,381 49,339,709 (51,587,750) $ (1,968,660)
Ending balance, shares at Jun. 30, 2022 279,380,263      
Beginning balance, value at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Beginning balance, shares at Mar. 31, 2022 274,601,664      
Issuance of common stock for services $ 79 16,071 16,150
Issuance of common stock for services, shares 78,600        
Employee stock options exercised $ 200 8,200 8,400
Employee stock options exercised, shares 200,000        
Issuance of vested options under the employee, director plan   99,106 99,106
Net Income (Loss)       (725,390) (725,390)
Issuance of common stock and warrants for cash through PPM $ 4,500 670,500 675,000
Issuance of common stock and warrants for cash through PPM, shares 4,499,999        
Ending balance, value at Jun. 30, 2022 $ 279,381 $ 49,339,709 $ (51,587,750) $ (1,968,660)
Ending balance, shares at Jun. 30, 2022 279,380,263      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - shares
3 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]        
Vested options issued under employee director plan 800,000 10,560,000 200,000 10,000
Warrants issued for services       1,166,667
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities    
Net Income (Loss) $ (2,766,347) $ (1,099,119)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 68,123 63,001
Stock based compensation for services 87,450 46,930
Net Issuance of options and warrants for services 1,415,383 84,748
Loss on Disposal of assets 40,099 33,484
Changes in operating assets and liabilities    
Prepaid expenses (66,896) (33,091)
Accrued interest - related party 13,424 (42,400)
Accounts payable and accrued liabilities 45,753 (508,768)
Forgiveness of PPP Loan (66,330)
Right of use lease (42,974) (39,227)
Net cash used in operating activities (1,205,985) (1,560,772)
Cash flows from investing activities    
Purchase of property and equipment (2,400) (114,673)
Patent Costs (18,273) (14,504)
Net cash from (used in) investing activities (20,673) (129,177)
Cash flows from financing activities    
Proceeds from exercise of warrants and options 15,900 1,315,717
Net proceeds from issuance of common stock 675,000 1,950,750
Net cash provided by financing activities 690,900 3,266,467
Net increase (decrease) in cash and cash equivalents (535,758) 1,576,518
Cash and cash equivalent at beginning of the period 1,164,664 286,579
Cash and cash equivalent at end of the period 628,906 1,863,097
Cash paid during the period for    
Interest
Taxes
Supplemental schedule of non-cash activities    
Cashless conversion of warrants/options
Conversion of convertible debenture to common stock $ 279,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
ORGANIZATION
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin. In early 2018, the Company’s Chief Executive Officer (“CEO”) Ben Slager invented a new technology system we call Cellulose-to-Sugar or CTS, and the Company filed a patent application for this technology. The CTS patent was awarded in 2021 in the United States (US10994255) and also in El Salvador. The Company also filed an application for this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. The Company has filed six more patents in the United States, all of which are currently pending. These patents broaden the scope and protection of the CTS technology.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin, as compared to the prior process which was a batch mechanical/chemical dry process previously used by our Company. The CTS creates molecular contact between two reactive solid components instead of a more conventional reaction where the reaction takes place between two liquid or gas components in a batch process. The reactants are (1) the cellulose, which is broken down into its components being sugars and lignin; (2) a catalyst, which is cost effective and abundantly available in the market from regular suppliers; it is recycled and reused in the process. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS differs from other commercial processes that are used to convert cellulose into sugar. Other processes use expensive enzymes, or expensive and harmful chemicals like strong acids or bases. Some use high temperature or high pressure steam. CTS can convert cellulosic material – including grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or king grass, and the cellulosic portion of municipal solid waste – into sugars and lignin, and the sugars subsequently into biofuels in a what is expected to be a cost effective and environmentally friendly way. The process times needed are significantly shorter than any other cellulosic process. CTS has a near zero carbon footprint in that the amount of added atmospheric carbon created by burning the biofuels produced by CTS is reabsorbed by the plant-based seed stock used in the CTS system. The CTS process recycles the water and catalyst.

 

At a commercial scale, our management expects to be able to produce ethanol more profitably than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process has much lower feedstock cost than corn, is uncomplicated and efficient as compared to other cellulosic ethanol processes, and is expected to have high value by-products and a highly valued D3 RIN that the Company expects to potentially receive for each gallon of ethanol. The Company believes a significant difference between CTS and corn ethanol is the wide range of feedstocks that CTS can process compared to corn. The CTS feedstocks are not food and have much lower costs than corn. In addition, while in corn ethanol only the corn is used, the CTS uses the whole plant or its waste products.

 

The new CTS technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

The Company has built several prototypes of the CTS system to solidify and further develop the process. The Company completed all the parameter optimizations possible in its lab and was able to generate a 99%+ conversion of the cellulosic material into soluble sugars suitable for further processing into cellulosic ethanol. The Company has recently contracted with K.R. Komarek to build larger scale systems, the first of which is anticipated to arrive before the end of the summer of 2022.

 

The goal of the first Komarek system is to process much larger volumes of feedstock to produce much higher volumes of sugars. Upon success, the Company anticipates ordering a larger system and building a semi-commercial scale pilot CTS plant around that. This will be an intermediate step to the final commercial-scale system. The Company believes that the semi-commercial scale plant will be sufficient to prove the commercial viability of the CTS technology. Due to its mechanical nature and modularity, management anticipates that one commercial-scale CTS plant would have multiple modular CTS systems. The Company expects to have the pilot plant running in 2023.

 

The CTS system converts plant-based feedstock into two product streams, cellulose and lignin, each of which can be converted into multiple products: (1) Cellulose is broken down into sugars. Sugar can be used to make biofuels, such as ethanol and sustainable aviation fuel, and may also be used to make specialty chemicals; and (2) Lignin can potentially be used in ion exchange resins, or to make specialty chemicals; It can also be burned as a renewable fuel.

 

 

Plan of Operation

 

The Company’s strategy is to diversify its product portfolio to include a number of product lines. These potentially include (1) biofuels – such as ethanol, or converting ethanol into higher biofuels like sustainable aviation fuel and the like; (2) selling sulfur-free lignin to ion exchange resin producers; (3) making specialty chemicals from lignin; and, (4) potentially making nanocellulose. We believe these, and other markets, could potentially provide for highly profitable products.

 

Our goal is to develop our CTS technology to a commercial scale and then seek to either enter into a joint venture or acquire existing corn ethanol plants to install the CTS technology. The Company is also looking into converting ethanol to sustainable aviation fuel. To minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin and other specialty chemicals from its patented CTS system.

 

Management believes that retrofitting existing plants with the CTS technology may achieve more rapid commercialization than building new plants. After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we expect that our profitability will potentially be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (“EPA”), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

The Company has also licensed the Vertimass Process to convert ethanol (from the CTS process) into sustainable aviation fuel. There is no up-front or annual fee until we are converting ethanol into SAF. The license agreement with Vertimass is the subject of a confidentiality agreement between the parties. Since we are not yet producing ethanol on a commercial scale, it is too preliminary to discuss details.

 

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
GOING CONCERN
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2022, the Company has incurred accumulated losses of $51,587,750. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our customers, employees and supply chain. Given the critical nature of the products that we provide, our office and lab have remained open during the pandemic. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:

 

   4/19/22   6/21/22 
Risk-free interest rate   2.93%   3.38%
Expected life   10 years    5 years 
Expected dividends   0%   0%
Expected volatility   133.42%   134.52%
BIOF common stock fair value  $0.165   $0.167 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $173,030 as of June 30, 2022 and $154,758 as of December 31, 2021.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2022, and June 30, 2021, the amounts charged to research and development expenses were $1,666,632, and $514,860, respectively.

 

Revenue Recognition

 

Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09:

 

  1. Identify contract(s) with a customer;
  2.

Identify the performance obligations in the contract;

  3. Determine the transaction price;
  4.

Allocate the transaction price to the performance obligations in the contract; and,

  5.

Recognize revenues when (or as) we satisfy the performance obligation.

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
PATENTS
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
PATENTS

NOTE 4 – PATENTS

 

The Company has been granted one patent on its technology, has filed for six others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $173,030 as of June 30, 2022.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
DEBT
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
DEBT

NOTE 5 – DEBT

 

Notes Payable – Chapter 11 Settlement

 

On July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $2,694,577 dollars plus stock warrants in the Circuit Court of the 15th Judicial Circuit in Palm Beach County, Florida. That lawsuit was moved to the Bankruptcy Court when the Company entered Chapter 11 on October 22, 2018. The Company filed a Complaint against Lenaburg on November 16, 2018, in the bankruptcy court in the Southern District of Florida. The bankruptcy judge ordered mediation, and a settlement was reached that paid Lenaburg $13,650 upon Plan Confirmation and a $50,000 claim payable out of post-confirmation net profits over 3 years, plus 1.5 million common stock warrants with a strike price of $0.30/share and a ten-year expiration period. The $50,000 is due on September 18, 2022.

 

Notes Payable – Related Parties

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the notes was $278,794.68 and $176,460 respectively. All of the notes were due on August 4, 2017 and then were in default. However, the notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company, or, at its option, may convert that into an equity investment in the first plant of the Company, measured by a percentage of the total cost to build, subject to a minimum equity interest of 1.25% in said plant.

 

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000 and are being amortized over the life of the note. The note’s maturity date was extended to 7/1/2018. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full, with no additional shares to be issued.

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the note was $14,382.2 and $8,588 respectively. The note was due on August 4, 2017 and was then in default. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018 and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500, and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30,

2022

  

December 31,

2021

 
Short Term Chapter 11 Settlement  $50,000   $50,000 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $2,788,132   $2,788,132 

 

Of the $2,788,132 due as of June 30, 2022, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $370,630, consisting of $200,630 due to related parties, $120,000 due to other, and a $50,000 Chapter 11 settlement.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
STOCKHOLDERS’ EQUITY
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 6 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of June 30, 2022, the Company had 279,380,263 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the six months ended June 30, 2022, the Company issued an aggregate of 526,381 shares of its common stock for services valued at $87,450.

 

For the six months ended June 30, 2022, the Company issued an aggregate of 4,499,999 shares of its common stock for cash valued at $675,000.

 

For the six months ended June 30, 2022, 350,000 employee stock options were exercised for proceeds of $15,900.

 

For the six months ended June 30, 2022, 687,500 warrants expired.

 

For the six months ended June 30, 2022, 2,604,466 options expired.

 

For the six months ended June 30, 2022, 11,360,000 stock options vested.

 

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.

 

On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believed the Complaint was frivolous. On June 28, 2022, Power Up Lending Group withdrew the case, and there was no financial cost to the Company or its Management team.

 

Leases

 

The Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022. Annual rent commenced at $84,100 per annum and increases 3% per year. Tenant is also required to cover operating costs that, as of January 1, 2022, are estimated at $3,379 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

Rent expense for the six months ending June 30, 2022, and 2021, were $64,724 and $63,921, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30,

2022

  

December 31,

2021

 
Right of Use Lease Liabilities          
Current portion   29,372    72,346 
Long-term portion   0    0 
TOTAL   29,372    72,346 

 

As of June 30, 2022, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2022   29,372 
2023   0 
2024   0 
      
TOTAL  $29,372 

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 5.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From June 30, 2022, to the date of this filing, the Company issued 34,000 shares for services.

 

From June 30, 2022, to the date of this filing, 150,000 warrants expired.

 

From June 30, 2022, to the date of this filing, 25,000 previously issued options vested.

 

From June 30, 2022, to the date of this filing, the Company issued 1,000,000 shares in a private placement for proceeds of $150,000.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:

 

   4/19/22   6/21/22 
Risk-free interest rate   2.93%   3.38%
Expected life   10 years    5 years 
Expected dividends   0%   0%
Expected volatility   133.42%   134.52%
BIOF common stock fair value  $0.165   $0.167 

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $173,030 as of June 30, 2022 and $154,758 as of December 31, 2021.

 

Research and Development

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2022, and June 30, 2021, the amounts charged to research and development expenses were $1,666,632, and $514,860, respectively.

 

Revenue Recognition

Revenue Recognition

 

Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09:

 

  1. Identify contract(s) with a customer;
  2.

Identify the performance obligations in the contract;

  3. Determine the transaction price;
  4.

Allocate the transaction price to the performance obligations in the contract; and,

  5.

Recognize revenues when (or as) we satisfy the performance obligation.

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

 

Fair Value Measurements

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION

The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:

 

   4/19/22   6/21/22 
Risk-free interest rate   2.93%   3.38%
Expected life   10 years    5 years 
Expected dividends   0%   0%
Expected volatility   133.42%   134.52%
BIOF common stock fair value  $0.165   $0.167 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
DEBT (Tables)
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
SCHEDULE OF NOTES PAYABLE

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30,

2022

  

December 31,

2021

 
Short Term Chapter 11 Settlement  $50,000   $50,000 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $2,788,132   $2,788,132 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30,

2022

  

December 31,

2021

 
Right of Use Lease Liabilities          
Current portion   29,372    72,346 
Long-term portion   0    0 
TOTAL   29,372    72,346 
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS

As of June 30, 2022, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2022   29,372 
2023   0 
2024   0 
      
TOTAL  $29,372 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
ORGANIZATION (Details Narrative)
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Renewable fuel description This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
GOING CONCERN (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated losses $ 51,587,750 $ 48,821,403
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) - Warrant [Member]
6 Months Ended
Jun. 30, 2022
$ / shares
Issuance Date April Nineteen Two Thousand Twenty Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 2.93%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 133.42%
BIOF common stock fair value $ 0.165
Issuance Date June Twenty One Two Thousand Twenty Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.38%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 134.52%
BIOF common stock fair value $ 0.167
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]          
Patents $ 173,030   $ 173,030   $ 154,758
Research and Development Expense $ 436,480 $ 249,786 $ 1,666,632 $ 514,860  
Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life     5 years    
Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life     10 years    
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
PATENTS (Details Narrative)
6 Months Ended
Jun. 30, 2022
USD ($)
Patents [Member]  
Finite-Lived Intangible Assets [Line Items]  
Legal and filing fees $ 173,030
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Short Term Chapter 11 Settlement $ 50,000 $ 50,000
Long Term Notes Payable from future revenue — Related Party 1,700,630 1,700,630
Long Term Notes Payable from future revenue — Other 120,000 120,000
Long Term Note Payable from future profits — Related Party 820,932 820,932
Long Term Note Payable from future profits — Other 96,570 96,570
TOTAL NOTES $ 2,788,132 $ 2,788,132
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Dec. 31, 2021
Equity [Abstract]            
Capital units, authorized 1,010,000,000       1,010,000,000  
Common stock, shares authorized 1,000,000,000       1,000,000,000 1,000,000,000
Common stock, par value $ 0.001       $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000       10,000,000 10,000,000
Preferred stock, par value $ 0.001       $ 0.001 $ 0.001
Common stock, shares issued 279,380,263       279,380,263 274,003,883
Common stock, shares outstanding 279,380,263       279,380,263 274,003,883
Preferred stock, shares Issued 0       0 0
Number of shares issued for services, shares         526,381  
Number of shares issued for services $ 16,150 $ 71,300   $ 46,930 $ 87,450  
Issuance of common stock and warrants for cash through PPM, shares         4,499,999  
Issuance of common stock and warrants for cash through PPM $ 675,000   $ 15,000 1,935,750 $ 675,000  
Employee stock options exercised, shares         350,000  
Employee stock options exercised       $ (0) $ 15,900  
Number of warrants expired         687,500  
Stock options expired         2,604,466  
Stock options vested         11,360,000  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Current portion $ 29,372 $ 72,346
Long-term portion 0 0
TOTAL $ 29,372 $ 72,346
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)
Jun. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2022 $ 29,372
2023 0
2024 0
TOTAL $ 29,372
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
6 Months Ended
Jan. 02, 2022
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Line Items]      
Operating costs $ 3,379    
Rent expense   $ 64,724 $ 63,921
Office and Laboratory Space [Member]      
Property, Plant and Equipment [Line Items]      
Lease description   The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021  
Lease extension period   This had been extended for one year until October 31, 2022  
Annual rent   $ 84,100  
Percentage of increase in rent per year   3.00%  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Aug. 05, 2022
Jun. 30, 2022
Subsequent Event [Line Items]    
Number of shares issued for services, shares   526,381
Number of warrants expired   687,500
Stock options vested   11,360,000
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Number of shares issued for services, shares 34,000  
Number of warrants expired 150,000  
Stock options vested 25,000  
Number of shares issued for private placement 1,000,000  
Proceeds from issuance of private placement $ 150,000  
XML 42 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001549145 2022-01-01 2022-06-30 0001549145 2022-08-05 0001549145 2022-06-30 0001549145 2021-12-31 0001549145 2022-04-01 2022-06-30 0001549145 2021-04-01 2021-06-30 0001549145 2021-01-01 2021-06-30 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2020-12-31 0001549145 us-gaap:PreferredStockMember 2020-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001549145 us-gaap:RetainedEarningsMember 2020-12-31 0001549145 2020-12-31 0001549145 us-gaap:CommonStockMember 2021-03-31 0001549145 us-gaap:PreferredStockMember 2021-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001549145 us-gaap:RetainedEarningsMember 2021-03-31 0001549145 2021-03-31 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001549145 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001549145 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001549145 2021-01-01 2021-03-31 0001549145 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001549145 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001549145 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 us-gaap:CommonStockMember 2021-06-30 0001549145 us-gaap:PreferredStockMember 2021-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001549145 us-gaap:RetainedEarningsMember 2021-06-30 0001549145 2021-06-30 0001549145 BIOF:IssuanceDateAprilNineteenTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-01-01 2022-06-30 0001549145 BIOF:IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-01-01 2022-06-30 0001549145 BIOF:IssuanceDateAprilNineteenTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-06-30 0001549145 BIOF:IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember us-gaap:WarrantMember 2022-06-30 0001549145 srt:MinimumMember 2022-01-01 2022-06-30 0001549145 srt:MaximumMember 2022-01-01 2022-06-30 0001549145 us-gaap:PatentsMember 2022-01-01 2022-06-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2022-01-01 2022-06-30 0001549145 2022-01-01 2022-01-02 0001549145 us-gaap:SubsequentEventMember 2022-07-01 2022-08-05 iso4217:USD shares iso4217:USD shares pure 0001549145 false --12-31 Q2 true false 10-Q 2022-06-30 2022 000-54942 BLUE BIOFUELS, INC. NV 45-4944960 3710 Buckeye Street Suite 120 Palm Beach Gardens FL 33410 888 607-3555 Common Stock par value $0.001 BIOF Yes Yes Non-accelerated Filer false true false 280414263 628906 1164664 111947 45051 740853 1209715 100189 273852 311334 377645 30276 30276 26341 65853 173030 154758 540981 628532 1281834 1838247 4000 11059 72670 72670 293606 240795 29372 72346 50000 50000 62714 49291 512362 496161 2521562 2521562 216570 216570 2738132 2738132 3250494 3234293 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 1000000000 1000000000 279380263 279380263 274003883 274003883 279381 274004 49339709 47151353 -51587750 -48821403 -1968660 -1396046 -1968660 -1396046 1281834 1838247 241507 293371 1044571 599648 436480 249786 1666632 514860 -40099 -40099 -33484 718086 543157 2751302 1147992 -718086 -543157 -2751302 -1147992 66330 66330 6712 6812 13424 13661 592 1896 1621 3796 -7304 57622 -15045 48873 -725390 -485535 -2766347 -1099119 -725390 -485535 -2766347 -1099119 -0.003 -0.002 -0.010 -0.004 275876745 266513255 275876745 266513255 274003883 274004 47151353 -48821403 -1396046 447781 448 70852 71300 150000 150 7350 7500 10560000 1316277 1316277 -2040957 -2040957 274601664 274602 48545832 -50862360 -2041926 78600 79 16071 16150 200000 200 8200 8400 800000 99106 99106 4499999 4500 670500 675000 -725390 -725390 279380263 279381 49339709 -51587750 -1968660 241721947 241722 43103607 -46682093 -3336764 223000 223 46707 46930 1166667 72090 72090 13455009 13455 1289362 1302817 9243331 9243 1926507 1935750 7080000 7080 271920 279000 10000 1215 1215 350000 350 12550 12900 177778 178 -178 -0 -613584 -613584 272251065 272251 46723780 -47295677 -299646 60000 60 14940 15000 200000 11443 11443 11443 11443 -485535 -485535 272311065 272311 46750163 -47781212 -758738 -2766347 -1099119 68123 63001 87450 46930 1415383 84748 -40099 -33484 66896 33091 13424 -42400 45753 -508768 66330 -42974 -39227 -1205985 -1560772 2400 114673 18273 14504 -20673 -129177 15900 1315717 675000 1950750 690900 3266467 -535758 1576518 1164664 286579 628906 1863097 279000 <p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqcYG0C5Nkm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_820_zicXtXbrcgu6">ORGANIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin. In early 2018, the Company’s Chief Executive Officer (“CEO”) Ben Slager invented a new technology system we call Cellulose-to-Sugar or CTS, and the Company filed a patent application for this technology. The CTS patent was awarded in 2021 in the United States (US10994255) and also in El Salvador. The Company also filed an application for this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. The Company has filed six more patents in the United States, all of which are currently pending. These patents broaden the scope and protection of the CTS technology.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin, as compared to the prior process which was a batch mechanical/chemical dry process previously used by our Company. The CTS creates molecular contact between two reactive solid components instead of a more conventional reaction where the reaction takes place between two liquid or gas components in a batch process. The reactants are (1) the cellulose, which is broken down into its components being sugars and lignin; (2) a catalyst, which is cost effective and abundantly available in the market from regular suppliers; it is recycled and reused in the process. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTS differs from other commercial processes that are used to convert cellulose into sugar. Other processes use expensive enzymes, or expensive and harmful chemicals like strong acids or bases. Some use high temperature or high pressure steam. CTS can convert cellulosic material – including grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or king grass, and the cellulosic portion of municipal solid waste – into sugars and lignin, and the sugars subsequently into biofuels in a what is expected to be a cost effective and environmentally friendly way. The process times needed are significantly shorter than any other cellulosic process. CTS has a near zero carbon footprint in that the amount of added atmospheric carbon created by burning the biofuels produced by CTS is reabsorbed by the plant-based seed stock used in the CTS system. The CTS process recycles the water and catalyst.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At a commercial scale, our management expects to be able to produce ethanol more profitably than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process has much lower feedstock cost than corn, is uncomplicated and efficient as compared to other cellulosic ethanol processes, and is expected to have high value by-products and a highly valued D3 RIN that the Company expects to potentially receive for each gallon of ethanol. The Company believes a significant difference between CTS and corn ethanol is the wide range of feedstocks that CTS can process compared to corn. The CTS feedstocks are not food and have much lower costs than corn. In addition, while in corn ethanol only the corn is used, the CTS uses the whole plant or its waste products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new CTS technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has built several prototypes of the CTS system to solidify and further develop the process. The Company completed all the parameter optimizations possible in its lab and was able to generate a 99%+ conversion of the cellulosic material into soluble sugars suitable for further processing into cellulosic ethanol. The Company has recently contracted with K.R. Komarek to build larger scale systems, the first of which is anticipated to arrive before the end of the summer of 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The goal of the first Komarek system is to process much larger volumes of feedstock to produce much higher volumes of sugars. Upon success, the Company anticipates ordering a larger system and building a semi-commercial scale pilot CTS plant around that. This will be an intermediate step to the final commercial-scale system. The Company believes that the semi-commercial scale plant will be sufficient to prove the commercial viability of the CTS technology. Due to its mechanical nature and modularity, management anticipates that one commercial-scale CTS plant would have multiple modular CTS systems. The Company expects to have the pilot plant running in 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CTS system converts plant-based feedstock into two product streams, cellulose and lignin, each of which can be converted into multiple products: (1) Cellulose is broken down into sugars. Sugar can be used to make biofuels, such as ethanol and sustainable aviation fuel, and may also be used to make specialty chemicals; and (2) Lignin can potentially be used in ion exchange resins, or to make specialty chemicals; It can also be burned as a renewable fuel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan of Operation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s strategy is to diversify its product portfolio to include a number of product lines. These potentially include (1) biofuels – such as ethanol, or converting ethanol into higher biofuels like sustainable aviation fuel and the like; (2) selling sulfur-free lignin to ion exchange resin producers; (3) making specialty chemicals from lignin; and, (4) potentially making nanocellulose. We believe these, and other markets, could potentially provide for highly profitable products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our goal is to develop our CTS technology to a commercial scale and then seek to either enter into a joint venture or acquire existing corn ethanol plants to install the CTS technology. The Company is also looking into converting ethanol to sustainable aviation fuel. To minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin and other specialty chemicals from its patented CTS system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management believes that retrofitting existing plants with the CTS technology may achieve more rapid commercialization than building new plants. After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we expect that our profitability will potentially be more consistent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (“EPA”), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. <span id="xdx_908_ecustom--RenewableFuelDescription_c20220101__20220630_zWfHR6eEmdz8" title="Renewable fuel description">This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has also licensed the Vertimass Process to convert ethanol (from the CTS process) into sustainable aviation fuel. There is no up-front or annual fee until we are converting ethanol into SAF. The license agreement with Vertimass is the subject of a confidentiality agreement between the parties. Since we are not yet producing ethanol on a commercial scale, it is too preliminary to discuss details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (“RINs”) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s mandate for cellulosic ethanol is for 620 million gallons for 2021, and 770 million gallons for 2022 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger quantities than they are now. The RFS mandate for 2022 calls for 20.77 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.77 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals may make 15% blending available year around. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $2.72 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation <p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zZLOMLQBwK3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_824_z712zszk4Sx3">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2022, the Company has incurred accumulated losses of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220630_zdQJNuujbUH2" title="Accumulated losses">51,587,750</span>. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our customers, employees and supply chain. Given the critical nature of the products that we provide, our office and lab have remained open during the pandemic. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -51587750 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zZbTqUwQNJoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_826_z3bAUv9jTjy4">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaFkEPvovIWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zzyN1A3hxfDe">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zGW2ij32PD1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvIMMxp5FnP">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zI3jQsWkZOse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zYie4TRtm7e4">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ze0rlCeEyoe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zaW8OI0VXXUj">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zfKbFAbbNyBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z3FHsvaAgD93">Stock Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_zDiZfqL79RD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zdrt1kEeCjT2">Stock-based Compensation Valuation Methodology</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zomCVmDJtiP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgTwpriFWnj3" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/19/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/21/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCIggpF5hGT4" style="width: 18%; text-align: right" title="Risk-free interest rate">2.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdaZ3TwgTeTh" style="width: 18%; text-align: right" title="Risk-free interest rate">3.38</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIlpFpRAeNC4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFIZUbTY9nZ7" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOz75b5D2g5k" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0TCeQGVkdek" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMeD9Wa5SIt8" style="text-align: right" title="Expected volatility">133.42</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zClXiwBDB3g9" style="text-align: right" title="Expected volatility">134.52</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx77T3GAnLZk" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGnfsCRCbGAc" style="text-align: right" title="BIOF common stock fair value">0.167</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zvNydQ3aEMh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zEpBqeUI1mgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z8NZAcrJSMT8">Property and Equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MinimumMember_zcr1sfDcaeKe" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MaximumMember_zVIUx9St2hVc" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z3nt9YCORVMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zJgGClVvctea">Patent Capitalization</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_909_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20220630_ziTqoiQNpRa7" title="Patents">173,030</span> as of June 30, 2022 and $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20211231_zCF3nzvEqqK5" title="Patents">154,758</span> as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf5bRuflJhIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z9PBrC4yY4R4">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all research and development costs as incurred. For the six months ended June 30, 2022, and June 30, 2021, the amounts charged to research and development expenses were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220630_zIlDkRYJqOXk">1,666,632</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210630_zUZRV4IhmK47">514,860</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBgZPzdK3el" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_ziwPpYACuoDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue Recognition</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify contract(s) with a customer;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance obligations in the contract;</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction price;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction price to the performance obligations in the contract; and,</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0; text-align: justify">Recognize revenues when (or as) we satisfy the performance obligation.</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_zqtxzAFgsUS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_ztfUHsIQF5h4">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqvYshTDCu15" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zONSfcFpLGo6">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zAZojU3ZOBm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zH38rrXDjEdf">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zIVlT8BAmjC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zB55a2sFpUJ">Profit (Loss) per Common Share</span>:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVfZZh2yfzx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zOBzBBnZ6XD1">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2298hSblq14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zEtYLrOdG0db">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</span></p> <p id="xdx_853_zfxgjTIFxH3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaFkEPvovIWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zzyN1A3hxfDe">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zGW2ij32PD1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvIMMxp5FnP">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zI3jQsWkZOse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zYie4TRtm7e4">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ze0rlCeEyoe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zaW8OI0VXXUj">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zfKbFAbbNyBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z3FHsvaAgD93">Stock Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_zDiZfqL79RD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zdrt1kEeCjT2">Stock-based Compensation Valuation Methodology</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zomCVmDJtiP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgTwpriFWnj3" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/19/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/21/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCIggpF5hGT4" style="width: 18%; text-align: right" title="Risk-free interest rate">2.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdaZ3TwgTeTh" style="width: 18%; text-align: right" title="Risk-free interest rate">3.38</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIlpFpRAeNC4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFIZUbTY9nZ7" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOz75b5D2g5k" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0TCeQGVkdek" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMeD9Wa5SIt8" style="text-align: right" title="Expected volatility">133.42</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zClXiwBDB3g9" style="text-align: right" title="Expected volatility">134.52</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx77T3GAnLZk" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGnfsCRCbGAc" style="text-align: right" title="BIOF common stock fair value">0.167</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zvNydQ3aEMh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zomCVmDJtiP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the 6 months ended June 30, 2022, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgTwpriFWnj3" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/19/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/21/22</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCIggpF5hGT4" style="width: 18%; text-align: right" title="Risk-free interest rate">2.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdaZ3TwgTeTh" style="width: 18%; text-align: right" title="Risk-free interest rate">3.38</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIlpFpRAeNC4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFIZUbTY9nZ7" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOz75b5D2g5k" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0TCeQGVkdek" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMeD9Wa5SIt8" style="text-align: right" title="Expected volatility">133.42</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zClXiwBDB3g9" style="text-align: right" title="Expected volatility">134.52</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilNineteenTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx77T3GAnLZk" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20220630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGnfsCRCbGAc" style="text-align: right" title="BIOF common stock fair value">0.167</td><td style="text-align: left"> </td></tr> </table> 0.0293 0.0338 P10Y P5Y 0 0 1.3342 1.3452 0.165 0.167 <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zEpBqeUI1mgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z8NZAcrJSMT8">Property and Equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MinimumMember_zcr1sfDcaeKe" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MaximumMember_zVIUx9St2hVc" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P10Y <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z3nt9YCORVMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zJgGClVvctea">Patent Capitalization</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_909_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20220630_ziTqoiQNpRa7" title="Patents">173,030</span> as of June 30, 2022 and $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20211231_zCF3nzvEqqK5" title="Patents">154,758</span> as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 173030 154758 <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf5bRuflJhIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z9PBrC4yY4R4">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all research and development costs as incurred. For the six months ended June 30, 2022, and June 30, 2021, the amounts charged to research and development expenses were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220630_zIlDkRYJqOXk">1,666,632</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210630_zUZRV4IhmK47">514,860</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1666632 514860 <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBgZPzdK3el" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_ziwPpYACuoDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue Recognition</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify contract(s) with a customer;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance obligations in the contract;</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction price;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction price to the performance obligations in the contract; and,</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0; text-align: justify">Recognize revenues when (or as) we satisfy the performance obligation.</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_zqtxzAFgsUS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_ztfUHsIQF5h4">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqvYshTDCu15" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zONSfcFpLGo6">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zAZojU3ZOBm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zH38rrXDjEdf">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zIVlT8BAmjC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zB55a2sFpUJ">Profit (Loss) per Common Share</span>:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVfZZh2yfzx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zOBzBBnZ6XD1">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2298hSblq14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zEtYLrOdG0db">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</span></p> <p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_zpTbP04wEq0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82B_zdiVdL6eIyc8">PATENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been granted one patent on its technology, has filed for six others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend_pp0p0_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkw0feeUjnG6" title="Legal and filing fees">173,030</span> as of June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 173030 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zt2Lr2vl84Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_824_zBCpOvLYpY3a">DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Chapter 11 Settlement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $2,694,577 dollars plus stock warrants in the Circuit Court of the 15<sup>th</sup> Judicial Circuit in Palm Beach County, Florida. That lawsuit was moved to the Bankruptcy Court when the Company entered Chapter 11 on October 22, 2018. The Company filed a Complaint against Lenaburg on November 16, 2018, in the bankruptcy court in the Southern District of Florida. The bankruptcy judge ordered mediation, and a settlement was reached that paid Lenaburg $13,650 upon Plan Confirmation and a $50,000 claim payable out of post-confirmation net profits over 3 years, plus 1.5 million common stock warrants with a strike price of $0.30/share and a ten-year expiration period. The $50,000 is due on September 18, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Related Parties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the notes was $278,794.68 and $176,460 respectively. All of the notes were due on August 4, 2017 and then were in default. However, the notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, &amp; Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company, or, at its option, may convert that into an equity investment in the first plant of the Company, measured by a percentage of the total cost to build, subject to a minimum equity interest of 1.25% in said plant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000 and are being amortized over the life of the note. The note’s maturity date was extended to 7/1/2018. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full, with no additional shares to be issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the note was $14,382.2 and $8,588 respectively. The note was due on August 4, 2017 and was then in default. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018 and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500, and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zqtOfHNenhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zFAcA0gCjg53" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zvm0UvMqQOHb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20211231_zl0EYTjYTsng" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzsoF_zQHZBI8xbGwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Short Term Chapter 11 Settlement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzsoF_zg7SW9mClMy8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzsoF_zeNfJUd9mDK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzsoF_z59s9yShWDF5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzsoF_zbuLMhO2DNB4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzsoF_z4eEgHkLi4s4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zLPW9uiRD4kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the $2,788,132 due as of June 30, 2022, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $370,630, consisting of $200,630 due to related parties, $120,000 due to other, and a $50,000 Chapter 11 settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zqtOfHNenhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zFAcA0gCjg53" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zvm0UvMqQOHb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20211231_zl0EYTjYTsng" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzsoF_zQHZBI8xbGwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Short Term Chapter 11 Settlement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzsoF_zg7SW9mClMy8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzsoF_zeNfJUd9mDK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzsoF_z59s9yShWDF5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzsoF_zbuLMhO2DNB4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzsoF_z4eEgHkLi4s4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 50000 50000 1700630 1700630 120000 120000 820932 820932 96570 96570 2788132 2788132 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVEizOGLbqVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_826_zUHSmtlcXtHa">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of capital stock, which the Company has authority to issue, is <span id="xdx_90F_eus-gaap--CapitalUnitsAuthorized_iI_pn6n6_c20220630_z6AllsPU0vI6" title="Capital units, authorized">1,010</span> million, <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pn9n9_c20220630_zBco6EUE0Js9" title="Common stock, shares authorized">1</span> billion of which are designated as common stock at $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220630_zkZALytviXA4" title="Common stock, par value">0.001</span> par value (the “Common Stock”) and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pn6n6_c20220630_zVQdUnSOmhWf" title="Preferred stock, shares authorized">10</span> million of which are designated as preferred stock par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220630_zHfdQRVyp68a" title="Preferred stock, par value">0.001</span> (the “Preferred Stock”). As of June 30, 2022, the Company had <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20220630_ztyjLiq694Tl" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20220630_z11FeiP7RK9l" title="Common stock, shares outstanding">279,380,263</span></span> shares of Common Stock issued and outstanding and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20220630_zjGhebicDT5k" title="Preferred stock, shares Issued"><span>no</span></span> shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220630_zpTbEG9kFEW1" title="Number of shares issued for services, shares">526,381</span> shares of its common stock for services valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20220101__20220630_zCOsqZOnZ9j3" title="Number of shares issued for services">87,450</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, the Company issued an aggregate of <span id="xdx_90C_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares_c20220101__20220630_zWSrnricrpCh" title="Issuance of common stock and warrants for cash through PPM, shares">4,499,999</span> shares of its common stock for cash valued at $<span id="xdx_902_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpm_pp0p0_c20220101__20220630_zKVRMEV6MQjg" title="Issuance of common stock and warrants for cash through PPM">675,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220630_zRQVoWNHXszf" title="Employee stock options exercised, shares">350,000</span> employee stock options were exercised for proceeds of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20220101__20220630_zXdDAcJfO7Fj" title="Employee stock options exercised">15,900</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20220630_zsSNEpm3uso5" title="Number of warrants expired">687,500</span> warrants expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20220630_zmhyKqjdhMBg" title="Stock options expired">2,604,466</span> options expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2022, <span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_c20220101__20220630_zQzkh3AW7Wm7" title="Stock options vested">11,360,000</span> stock options vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1010000000 1000000000 0.001 10000000 0.001 279380263 279380263 0 526381 87450 4499999 675000 350000 15900 687500 2604466 11360000 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z1ttZ5952AQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_820_z8fI5edOc1R">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&amp;O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believed the Complaint was frivolous. On June 28, 2022, Power Up Lending Group withdrew the case, and there was no financial cost to the Company or its Management team.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zpOW2pQ4TCwg" title="Lease description">The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021</span>. <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zNS6WUTM3r91" title="Lease extension period">This had been extended for one year until October 31, 2022</span>. Annual rent commenced at $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zMx0cYm9mOS5" title="Annual rent">84,100</span> per annum and increases <span id="xdx_907_ecustom--PercentageOfIncreaseInRentPerYear_pid_dp_uPure_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zCyTDShtYGIb" title="Percentage of increase in rent per year">3</span>% per year. Tenant is also required to cover operating costs that, as of January 1, 2022, are estimated at $<span id="xdx_905_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20220102_zDeJg6at41Wi" title="Operating costs">3,379</span> per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General &amp; Administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent expense for the six months ending June 30, 2022, and 2021, were $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20220101__20220630_zLnJHOyGsp4e" title="Rent expense">64,724</span> and $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20210101__20210630_zW2T1vmuT0ni" title="Rent expense">63,921</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zNwbjlN8WNH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zfZKW4TLihq5" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220630_z7kRDEDza7ld" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zpVysCWwl9rk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzC2m_zeBfAZ2Ccqqi" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">29,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">72,346</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzC2m_zJW7EXuUTFJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzC2m_zgqccjCb8Bn7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,372</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">72,346</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A1_ztjbZFBU8F02" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYZQM8DeeMlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zKYBRVXtNb55" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zjNKcwn7sVmj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzMHu_zVwQfhAPw0I3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 75%; text-align: right">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right">29,372</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzMHu_zHb5QYB5FRT9" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzMHu_zot6xsaIQwf6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzMHu_zxLRBNZucL9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,372</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AD_ziEOhdzIvqB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021 This had been extended for one year until October 31, 2022 84100 0.03 3379 64724 63921 <p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zNwbjlN8WNH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zfZKW4TLihq5" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220630_z7kRDEDza7ld" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zpVysCWwl9rk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzC2m_zeBfAZ2Ccqqi" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">29,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">72,346</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzC2m_zJW7EXuUTFJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzC2m_zgqccjCb8Bn7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,372</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">72,346</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 29372 72346 0 0 29372 72346 <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYZQM8DeeMlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zKYBRVXtNb55" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zjNKcwn7sVmj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzMHu_zVwQfhAPw0I3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 75%; text-align: right">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right">29,372</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzMHu_zHb5QYB5FRT9" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzMHu_zot6xsaIQwf6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzMHu_zxLRBNZucL9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,372</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 29372 0 0 29372 <p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zMeipzhwodb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_82A_zDD1KQqNIV0i">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 5.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zq3GmldI06Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_826_zWoETvBwDJSb">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From June 30, 2022, to the date of this filing, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20220805__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zj011wExakOj" title="Number of shares issued for services, shares">34,000</span> shares for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From June 30, 2022, to the date of this filing, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220701__20220805__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztgM4JHg088c" title="Number of warrants expired">150,000</span> warrants expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From June 30, 2022, to the date of this filing, <span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_c20220701__20220805__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2Dj1dl2uRE3" title="Stock options vested">25,000</span> previously issued options vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From June 30, 2022, to the date of this filing, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220805__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGSGPRJzmyG8" title="Number of shares issued for private placement">1,000,000</span> shares in a private placement for proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220701__20220805__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8e76nBDUtni" title="Proceeds from issuance of private placement">150,000</span>.</span></p> 34000 150000 25000 1000000 150000 EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 63 179 1 false 12 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://bluebiofuels.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://bluebiofuels.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Operations (Unaudited) Sheet http://bluebiofuels.com/role/StatementOfOperations Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION Sheet http://bluebiofuels.com/role/Organization ORGANIZATION Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://bluebiofuels.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PATENTS Sheet http://bluebiofuels.com/role/Patents PATENTS Notes 11 false false R12.htm 00000012 - Disclosure - DEBT Sheet http://bluebiofuels.com/role/Debt DEBT Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://bluebiofuels.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://bluebiofuels.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://bluebiofuels.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://bluebiofuels.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - DEBT (Tables) Sheet http://bluebiofuels.com/role/DebtTables DEBT (Tables) Tables http://bluebiofuels.com/role/Debt 19 false false R20.htm 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://bluebiofuels.com/role/CommitmentsAndContingencies 20 false false R21.htm 00000021 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://bluebiofuels.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://bluebiofuels.com/role/Organization 21 false false R22.htm 00000022 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://bluebiofuels.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://bluebiofuels.com/role/GoingConcern 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Sheet http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Details 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - PATENTS (Details Narrative) Sheet http://bluebiofuels.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://bluebiofuels.com/role/Patents 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 26 false false R27.htm 00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://bluebiofuels.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details) Sheet http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details) Details 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Details 29 false false R30.htm 00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://bluebiofuels.com/role/CommitmentsAndContingenciesTables 30 false false R31.htm 00000031 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://bluebiofuels.com/role/SubsequentEvents 31 false false All Reports Book All Reports form10-q.htm biof-20220630.xsd biof-20220630_cal.xml biof-20220630_def.xml biof-20220630_lab.xml biof-20220630_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 6, "contextCount": 63, "dts": { "calculationLink": { "local": [ "biof-20220630_cal.xml" ] }, "definitionLink": { "local": [ "biof-20220630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "biof-20220630_lab.xml" ] }, "presentationLink": { "local": [ "biof-20220630_pre.xml" ] }, "schema": { "local": [ "biof-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 273, "entityCount": 1, "hidden": { "http://bluebiofuels.com/20220630": 18, "http://fasb.org/us-gaap/2022": 44, "http://xbrl.sec.gov/dei/2022": 6, "total": 68 }, "keyCustom": 23, "keyStandard": 156, "memberCustom": 3, "memberStandard": 9, "nsprefix": "BIOF", "nsuri": "http://bluebiofuels.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bluebiofuels.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PATENTS", "role": "http://bluebiofuels.com/role/Patents", "shortName": "PATENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - DEBT", "role": "http://bluebiofuels.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://bluebiofuels.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://bluebiofuels.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://bluebiofuels.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "role": "http://bluebiofuels.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - DEBT (Tables)", "role": "http://bluebiofuels.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "role": "http://bluebiofuels.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "BIOF:RenewableFuelDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ORGANIZATION (Details Narrative)", "role": "http://bluebiofuels.com/role/OrganizationDetailsNarrative", "shortName": "ORGANIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "BIOF:RenewableFuelDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://bluebiofuels.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_IssuanceDateAprilNineteenTwoThousandTwentyTwoMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "role": "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "shortName": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_IssuanceDateAprilNineteenTwoThousandTwentyTwoMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_srt_MinimumMember", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_PatentsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - PATENTS (Details Narrative)", "role": "http://bluebiofuels.com/role/PatentsDetailsNarrative", "shortName": "PATENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_us-gaap_PatentsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableToBankNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "role": "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableToBankNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details)", "role": "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails", "shortName": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "role": "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-01-02", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-01-02", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-08-05_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statement of Operations (Unaudited)", "role": "http://bluebiofuels.com/role/StatementOfOperations", "shortName": "Consolidated Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://bluebiofuels.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - ORGANIZATION", "role": "http://bluebiofuels.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "role": "http://bluebiofuels.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "BIOF_CashlessConversionOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless conversion of warrants.", "label": "Cashless conversion of warrants/options" } } }, "localname": "CashlessConversionOfWarrants", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Purchase Warrants And Other Derivative Financial Instruments [Policy Text Block]", "label": "Common Stock Purchase Warrants and Other Derivative Financial Instruments" } } }, "localname": "CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BIOF_ConversionOfConvertibleDebentureToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debenture to common stock.", "label": "Conversion of convertible debenture to common stock" } } }, "localname": "ConversionOfConvertibleDebentureToCommonStock", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_IncreaseDecreaseInForgivenessOfLoan": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in forgiveness of loan.", "label": "IncreaseDecreaseInForgivenessOfLoan", "negatedLabel": "Forgiveness of PPP Loan" } } }, "localname": "IncreaseDecreaseInForgivenessOfLoan", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_IncreaseDecreaseInRightOfUseLease": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right of use lease.", "label": "Right of use lease" } } }, "localname": "IncreaseDecreaseInRightOfUseLease", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_IssuanceDateAprilNineteenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date April Nineteen Two Thousand Twenty Two [Member]", "label": "Issuance Date April Nineteen Two Thousand Twenty Two [Member]" } } }, "localname": "IssuanceDateAprilNineteenTwoThousandTwentyTwoMember", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date June Twenty One Two Thousand Twenty Two [Member]", "label": "Issuance Date June Twenty One Two Thousand Twenty Two [Member]" } } }, "localname": "IssuanceDateJuneTwentyOneTwoThousandTwentyTwoMember", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash through Ppm.", "label": "Issuance of common stock and warrants for cash through PPM" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpm", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock and Warrants for Cash Through PPM Shares.", "label": "Issuance of common stock and warrants for cash through PPM, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BIOF_LoanForgiveness": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loan forgiveness.", "label": "LoanForgiveness", "negatedLabel": "Loan Forgiveness" } } }, "localname": "LoanForgiveness", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotePayableFromFutureProfitsOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 5.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term note payable from future profits other.", "label": "Long Term Note Payable from future profits \u2014 Other" } } }, "localname": "LongTermNotePayableFromFutureProfitsOther", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotePayableFromFutureProfitsRelatedParty": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 4.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term note payable from future profits related party.", "label": "Long Term Note Payable from future profits \u2014 Related Party" } } }, "localname": "LongTermNotePayableFromFutureProfitsRelatedParty", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotesPayableFromFutureRevenueOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 3.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Notes Payable From Future Revenue Other.", "label": "Long Term Notes Payable from future revenue \u2014 Other" } } }, "localname": "LongTermNotesPayableFromFutureRevenueOther", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotesPayableFromFutureRevenueRelatedParty": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term notes payable from future revenue related party.", "label": "Long Term Notes Payable from future revenue \u2014 Related Party" } } }, "localname": "LongTermNotesPayableFromFutureRevenueRelatedParty", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and Laboratory Space [Member]", "label": "Office and Laboratory Space [Member]" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BIOF_PaymentsForPatentCosts": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for patent costs.", "label": "PaymentsForPatentCosts", "negatedLabel": "Patent Costs" } } }, "localname": "PaymentsForPatentCosts", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_PercentageOfIncreaseInRentPerYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in rent per year.", "label": "Percentage of increase in rent per year" } } }, "localname": "PercentageOfIncreaseInRentPerYear", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "BIOF_RenewableFuelDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewable Fuel Description.", "label": "Renewable fuel description" } } }, "localname": "RenewableFuelDescription", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "BIOF_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options vested.", "label": "Stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BIOF_StockIssuedDuringPeriodSharesStockOptionsExercised1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised 1.", "label": "Employee stock options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "BIOF_StockIssuedDuringPeriodSharesWarrantsExercisedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercised, shares.", "label": "Warrants exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedShares", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "BIOF_StockIssuedDuringPeriodValueStockOptionsExercised1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised 1.", "label": "Employee stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised1", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "BIOF_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants exercised.", "label": "Warrants exercised" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "BIOF_StockbasedCompensationValuationMethodologyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockbased Compensation Valuation Methodology [Policy Text Block]", "label": "Stock-based Compensation Valuation Methodology" } } }, "localname": "StockbasedCompensationValuationMethodologyPolicyTextBlock", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BIOF_StockholdersEquityDeficit": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders Equity Deficit.", "label": "StockholdersEquityDeficit", "totalLabel": "TOTAL EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityDeficit", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BIOF_WarrantsIssuedForService": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued for service.", "label": "Warrants issued for services" } } }, "localname": "WarrantsIssuedForService", "nsuri": "http://bluebiofuels.com/20220630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r354", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r139", "r140", "r141", "r142", "r156", "r171", "r199", "r200", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r329", "r330", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r139", "r140", "r141", "r142", "r156", "r171", "r199", "r200", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r329", "r330", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r135", "r139", "r140", "r141", "r142", "r156", "r171", "r198", "r199", "r200", "r233", "r234", "r235", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r329", "r330", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r135", "r139", "r140", "r141", "r142", "r156", "r171", "r198", "r199", "r200", "r233", "r234", "r235", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r329", "r330", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r67", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEETS" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r27", "r66", "r290", "r291" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable - Related Party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated depreciation and amortization on property and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r69", "r70", "r71", "r238", "r239", "r240", "r266" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r202", "r242", "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Issuance of vested options under the employee, director plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r155", "r183", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of 1,166,667 warrants for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r237" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation for services" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r14", "r64", "r103", "r106", "r112", "r118", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r259", "r262", "r269", "r294", "r296", "r314", "r320" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r25", "r64", "r118", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r259", "r262", "r269", "r294", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r64", "r118", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r259", "r262", "r269", "r294" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "TOTAL OTHER ASSETS" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r229", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r229", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital units, authorized" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r11", "r54" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r47", "r54", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalent at end of the period", "periodStartLabel": "Cash and cash equivalent at beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r47", "r270" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r143", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r69", "r70", "r266" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r183" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.001 par value; 1,000,000,000 shares authorized; 279,380,263 issued and outstanding at June 30, 2022, and 274,003,883 shares issued and outstanding at December 31, 2021." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r59", "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r62", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r52", "r130" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r27", "r66", "r289" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Deferred wages and director\u2019s fees - Related party" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r74", "r75", "r76", "r77", "r78", "r82", "r83", "r85", "r86", "r87", "r90", "r91", "r267", "r268", "r318", "r327" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Profit (Loss) per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r37", "r38", "r39", "r69", "r70", "r71", "r73", "r79", "r81", "r92", "r119", "r183", "r185", "r238", "r239", "r240", "r253", "r254", "r266", "r271", "r272", "r273", "r274", "r275", "r276", "r286", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r122", "r123", "r125", "r126", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend": { "auth_ref": [ "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of capitalized costs incurred in the period to renew or extend the term of a recognized finite-lived (amortizing and amortizable) intangible asset.", "label": "Legal and filing fees" } } }, "localname": "FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r122", "r124" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r125" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r52" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 }, "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of assets", "negatedTerseLabel": "Loss on Disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r72", "r103", "r105", "r108", "r111", "r113", "r118", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r258", "r268", "r269" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income (Loss) before provisions for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r65", "r80", "r81", "r102", "r248", "r255", "r256", "r328" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provisions for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r36", "r246", "r247", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r51" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest - related party" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r51" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r51" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "PATENTS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/Patents" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r60", "r124", "r308", "r309", "r310", "r312" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patent Capitalization" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest expense - other" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense - related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r46", "r48", "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable - Related Party" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r52" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Net Issuance of options and warrants for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lease description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r284" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "TOTAL" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r284" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r284" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r284" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lease extension period" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r64", "r107", "r118", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r260", "r262", "r263", "r269", "r294", "r295" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r64", "r118", "r269", "r296", "r316", "r324" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r30", "r64", "r118", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r260", "r262", "r263", "r269", "r294", "r295", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r15", "r16", "r64", "r118", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r260", "r262", "r263", "r269", "r294", "r295" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r47" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r47" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r50", "r53" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r34", "r35", "r39", "r40", "r53", "r64", "r72", "r74", "r75", "r76", "r77", "r80", "r81", "r84", "r103", "r105", "r108", "r111", "r113", "r118", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r268", "r269", "r317", "r326" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "totalLabel": "Net Income / (Loss):" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental schedule of non-cash activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other (income) expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r15", "r315", "r322" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "totalLabel": "TOTAL NOTES" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r32", "r66", "r289" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes Payable \u2014 Related Party" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Chapter 11 Settlement" } } }, "localname": "NotesPayableToBankCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankNoncurrent": { "auth_ref": [ "r15", "r315", "r321" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Short Term Chapter 11 Settlement" } } }, "localname": "NotesPayableToBankNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r103", "r105", "r108", "r111", "r113" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations:" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r283", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Annual rent" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r279" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "TOTAL" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r279" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease Liability - Current", "verboseLabel": "Current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r279" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r278" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of Use Assets, net of accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r31" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Notes Payable \u2014 Other" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r44" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r169" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r169" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r24", "r120", "r121" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r45" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from issuance of private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r45" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants and options" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r133", "r296", "r319", "r325" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net of accumulated depreciation and amortization of $100,189 and $273,852 at June 30, 2022 and December 31,2021, respectively." } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r133", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r287", "r288", "r289", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r245", "r307", "r342" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & Development", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r185", "r296", "r323", "r334", "r335" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated losses" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r69", "r70", "r71", "r73", "r79", "r81", "r119", "r238", "r239", "r240", "r253", "r254", "r266", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r100", "r101", "r104", "r109", "r110", "r114", "r115", "r116", "r195", "r196", "r311" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r61", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r122", "r124", "r312" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/PatentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r217", "r224", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r201", "r203", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r229", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r13" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposits" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Number of warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Stock options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r207", "r230", "r231", "r232", "r233", "r236", "r241", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "BIOF common stock fair value" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested options issued under employee director plan" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r37", "r38", "r39", "r69", "r70", "r71", "r73", "r79", "r81", "r92", "r119", "r183", "r185", "r238", "r239", "r240", "r253", "r254", "r266", "r271", "r272", "r273", "r274", "r275", "r276", "r286", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r69", "r70", "r71", "r92", "r311" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r17", "r18", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Issuance of common stock in exchange for debt, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r183", "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued for private placement" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r183", "r185", "r213" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Cashless exercise of stock options, shares", "verboseLabel": "Employee stock options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r33", "r183", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Issuance of common stock in exchange for debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock for services", "verboseLabel": "Number of shares issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r183", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Cashless exercise of stock options", "verboseLabel": "Employee stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r64", "r117", "r118", "r269", "r296" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "BIOF_StockholdersEquityDeficit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r63", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r185", "r186", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r277", "r298" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r277", "r298" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r277", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r277", "r298" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r297", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid during the period for" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r93", "r94", "r95", "r96", "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r82", "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1),20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r343": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r345": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r346": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r347": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r348": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r349": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r350": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r351": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r352": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r354": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r355": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r356": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r357": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r358": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r359": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r360": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r361": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r362": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r363": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" } }, "version": "2.1" } ZIP 50 0001493152-22-021543-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-021543-xbrl.zip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

F7!([Y MHBN?QWP "R4;"R6LE S_)1%H7/KDLB";.#)>77:+A4:C@A5^6!W&=LKP3LLS MNI9W9=F<9* )/WQ S,_/GYF8A8*&3ZPO\*7FY=&J:I)D+WSIR@*;\CU/6\V4C32XXS M%3:15&N0<#!:%:$MJ-W4(69EA9CU&TO-#CZ$774CI-X(KRH98:PQ.VH4M9%\ M_>A'W_*#@;P!J][<,.<'GO))".0F.!=2&BA% TSN".FBVF!'>W U^/ D_T+O MIZ?ZO8ND#-_Q]#L!KVADQ#Q=9 T%"=A9#MJ:&!7YSV#L3/ ?VULV#B9>0-XA MTP.Q+;HBE+2MLX]95<0UJ>LR419U=">!(9J_,RVY,@H=23.6.*+1MV+X]XV3 MT; F)($P2QZ(7MS0E-L.0H>8Z"0 QI*@6X5,ND&VQ*1!(LPU\ M<9]A@RT;+Y5%-QT$14#BA-D$OXD.:'0>BP04\:O8^HJIE1A'SGS-<[\E+EFA M([$UZF-J ^1EHX70B(1\0][QJOB:$^C5"9BR!$-D],/@*WP&_1Q\'.@6TC[1 M=QB33KPA/:2_C%>EUT@/5HP69:R-"/MO35GN],%4M;(N-^5M8/<)%3H8,'FIY@#BDH*K"XX 90)G:5QE.5?Q&5"#+9 M=NB0!$;,LQ4DBPF%+-,X0<#%3@EP:B! AWC:UP,DP\ M0])N!#?N*[I8PP =80/7)A<:>LG1S8:)>SCVV,5L%6="OAPJ\Q+R[\BE@;] MOC39929G^6KZY'P52W 'BM#9EXTY3:D>-PHQFQ9F?1T$M@ET/<4TUR%,&'EQ M#&QEABFXXM_H((%9$PNVDT$,[[%"#SPVF(IEP2*G.-6O:OQ4T4AGM;TEVG)1 MHFOBNURQA)DO?44)I&3Y[UF^883( >DU8^"L.^HNC080(AW M.,X2.?@_!%9-8Q[,2%E7, 63'!1M@6D_Q_PZL>.LD=(UXZ9Z*Z MGR8I,5KM&'931[)4D7!T"JHP'$SM!B''%@B5$X)'2/T#U0)DH\_)W\YWE^L6 M:=\;!"%QLXX?W""?$J$+,-PA1AG6:/SQ_PD[(-)**.98 T*M#CSL"9CJT*0^$/XN M5.L1:V"'*8$U%M6%Y1(=*'U)$RO*\Q<5Q(Z'"7J':),[^"DAQHM0+5;L%Z7+7N)PBU"(9L-\Z M$^57Q("6&O!Q I>(0;>WQ!?QRA"E\5\C,,1W%C5O8^IZ 2MKI/< 86&G!5+A M9 4G%^YKGPHR4JA@XMA8'Q4-\:E2DEV?=&LY^ X-+F>2O2E"^=2 02MF1O.1 M7X\2J5C+;92%I-1K5[(Y@'C5,?%\$ M<+!MT>9>/XJ83$6?<#5%&<>#,EY83*"?6]QF]'4Y%K!TS;6FNW+(/E,L'DVE MOB._01X,&$Y2S_:6M$#^)#_X0>JLR_%]2P;"@5PQLO3W3:ROCA:*EA5ZI:U$ M#FO82PMN- I)"VX5AU#A>9-]>PA-HUCKXK!42LORL"*N=/LQR@Z][,<<<".; M4#-9Y1@HZS&>+J%_H0/"EUV+2\.#]9Z.W^:JM')"Z$]")0,]5FD,'F>_N3 / MCV5",!X%T!4:;X-E>ER%7H%&"*WIC&9"\P";"O5C4-M1_$D>A0[I(>CS ZSEHP57F4D&VAYPMKX4DG M, <,5O$B+9#_U>$X7H25*2G,YX$:OS,,'4?";&AY2^PE]?C! &4L$,Y8RV4V MQG$5&32$3YO&JXIZ(0,@R'C8"&(AV*9$G!#>VA384GTKI7(X%$$/_A5[-W\K M']33GG(G"84^+VZ.,&TIT)Y1*-+@($3 MC*B+,))>JW8FQ>VM +*FY>2K$86BA!"S';M\^4AC M6''+8,2 NV_#!J&'6)28Q'#8%NG7SA'1V6CO0+&8[2%V)<]$X:89M MX%?:PCE $Q/%O\8=R6X16=)R<[1]44Y[+4*0X]Q/52\-][_RIA./U.$CPI)Y M5H3\#._>B989E344)64PZ X5P1.]56C6ZL("046^8*B7U"EQ&<'Q@, M$\P-&5#Q(;63WI;J0'9"0 ,@+2']T6?J8,>9*\'^ N#= M8/P7C 6ID$]+7N"#-G(@,9=,I5=6%#/L%3TE2>0(.<.)=JD]2[+$#165LV?% M=J9$VV*" BLT]!)$K[+W5B]X/ U=KE%"D3>IL:G?*D]JUU7M4526&,*1?.'\ M0,J44^7 *OXVPN^+C#18ZXC*^V/[#=#QT-@>@0(HJIOBYFE"04-H73O"\2(\ M.\G"DK>W2)PMF*S$3"B!)XHW:3*/@!O >K/(EE.("+%A.C-71C#8[R8:+&'V M'$(EC1'>&I\<>6"43EQ,^&S[W+*!L)'F@J,@6LS4#-U1$.)0L2.T#VYDY CT MGS5%U9U@D?1I)CH!4VF=-95-QL!])'WJ6$;I9['*:H/;]AXSMN*9T(4HXQ&! MK582CP.1U*BPZ]2_B>K:;V^U!0/8[>Z::N$BH]-D>P6KDB/,:F 1^(ES//%_ M$REX]!1+TAQYYRC+%B[E(!880C]!4 25BH)QK*&#[E)@&B&(;MX: 3A:V%:! MRA6 /1T@XZ(EU>VQ%(;F98H$$A=ELJBPA5C+JC\$LAZ>A+TA\ M@[D<(:% (*M&8A'<^X&SX)#5W;ZAY2I1ZSNX ,R3&X Z$5M>FE] ;B>D+)'J M38Z[/!4X^R4F7-IS6N5JTI4A'UV%(45(HDAD/7BX'RC<(R57-CSJ,:1YB[&! M9URW;B#T\"X-1:$W 8H3C'*20M\NN MT?*OW# @FN!TD5AT>VN."'DK8K3RUY3!]4MS%ISJ43S)D'ZP/ F.$!-QK#N^FNMK-=!;EL'EQ*N4GG[=-(94XA M9P$FY(I+M("?6CN'%+"X(A$&0W$(XHC834\YW-M;+&QHDR7V*C8.=P8!;A&K M6GBWA9;%/$H&MQ9\VX@4$[@L?)U6H*6@25.?DYJ1KLG,U;&I,D@NF* NMF 8 M]D5Q>C_F(.!_!5$Q3UZVN%W>QUJI8,"%\G"O>#OY]YCZQ3M3KZLGP,S)/E+B M!#U8G?C::T%3\N-4A-Y'1"E."2$,,V/FB%0,-Q(2 82G-Y/OV,+92>]DNXCP M25'/#P0JBC"M!MOE1SUO26408YO8&9# "N@ TG9%*2XB'J,H1@,PPE3$%[]A MZTJ2]P@(L'PN@H%JB1]<\P&='W4S)T";A=E\[9'Z=5_IP#I.RZOJWZ%W+?L*A;.MA9E2]'7.EO!Z9#$29#W&-*&H5"(#H=5GX+O%PA\F/\U7D_=^>>)H M2223%>QC%QC:@%0 NH"6Q\4A*"16K/[!*V6M5%6$X1M L7S>7=%+E E8H$JE MV88DEGVG*A*P,2]+N_62#K;5+;F+@+@\]@*5&71TQR27 MS[I*V(I#?^@4MUSH+I&:H>3'>,=CX* PIVC9%<-^3>6$#63H::/Q/#:0C/W- MY)<2&LX'=#9/K(B4 -+[M9P32?ZO5+*EAJ]^+8/9JUW38VY: CQQ>RN9[L H MW'?4\GW,I1TZC@$7S?70R+="9V7DJ=L\XELBIIZZ#I@+I(L0(E;:AI0>AVV6 MN*R(Q0Z#].V,+X1;!$IGAY@2>CAFCE1U])FA59B#E.<;&0?H[':0M5#!#M(@ MJ$8*Z VP7][&>?>HQ)_U56=K4LE.DE@AAKQUA.[1D/=DCH8NX8*% ! Q)]6K M6"\N(.7SP)G&1H;U"6\V.JU35LY:B_BVMXYD#;,-H.G1.CI8H,9AJUO5TV&QG1WFG:WNZ8"HP!'H8B/Q M:+56,,M[1=DG0!3C1/%)->T0Q*DWRA(Y>*#/Q<;+1LFL5@N_@5A[VE/N^*"[ M3$-0V4N-]-0S6203AWP+7-,H0*\9^ ZXIO;(]?X-1V?2I;:!M>0#60 MN#"=2_XWJCK!Y7&N@Y# +%++LQU9#8NCG!BSP60G7Z8P(Z0D+7 G7MLUFK$A M6]EM;RUKP&/+SOE8E(13+^'+62KM@49:%.4S['3^UF"03! 0DZX%GZ\6S>I> MW:Q7"W)IA"@4RR/'>+HA6I(BC9OQ8VH@5S$^MROQ':U;">L^A.JAFCU6&.\D M4X,JT;GL(6]R\A8Z3&GQ[.7'8D?H0*6R3G:0].&#?5GB:*G_B0 LOTBRX-R90*S.,VD2W! 21"%=(J*)0<1XS-@1&#/B,HU'*WMS+8=A&S M2"-166#172?I2C >H-IKA032U\6\R'\9 I.RDQIXCCLEP[Z<',DR(LP4E.+ M/IN9MVDY\TBMN]PW=/%#-PI\55T8%#3'$8U/L)BN#ZQ1V'\,7,CT M,S5>@=S@EDZO\3KI?RS^]S_NF\U9/H*J'7"OAKRSB_).+2NY0< $("OG&',K M:-$VPEU,1>>40/P-SW7#&1_W0&]YD$I\RY8[A">R,4N..Z1<.4JX89-3 4WK MSTC5VJM5Z)1+%5"["G46F"]+C;)9KA>IK"P=/8/%EKF'50^-*G*;-UR%V4& A!0AB6LU>6Y%42GRX6"F:-JK +2)[ZT/86=UWB MBC,#PG1R]Q_0'YT1#(QJ*,-R)#9:ELB739*L$6HFHI!/VHR.F]6DU2PVM/YH MM'X'EG4G2D]!F$CIE4K%;)3*1.I%LP _5>M%HKCMK9?51L.L5?:,++&GB,RU MQ%YI5,UJN90!<"*V/YX)C/U :SPO:;QH5BKE#:T]TI2QHP%6S<7JU$0=&AL4 M !?1A"]7UT'Z@0,K,/74S7*A(LYQSZP7-+*1WS%6?B8E=JQYF_^IDEDIEIA0 MJT"I54DS=;-2K6]HYFGQIR6-BCJ)^(&_,["B,>4IN2%',)!=8*B#O1R5@ED MMK-8E?]EN6Q6]BI95K2]=2W2(5/.8[L1J&A"_/V'PL1<;0+QP&D+ O%%/Z", M1$KWIVPH9%*84(!AG TM/?"4P=R%;1Z,.0M,Q]*].O]_UF3ZU^%K44A69DNM M8T?D#']9*=> 4 HFUT$3HH=\X7LUL]:0'*I4 5ULKZ;3$S4+2&65F($F.->( M.S\CYJ;6+ P\#B!7,1933-N4C%T9!]=3S65##-%SZ"7<@&*A=AN1J:P0O1CR M%><_4J\5$2H0RN2&II\<3=_ 2)FLBV:M!O1;+N40MED$>Z5>EX9"M5@!ZR6U M3KDYT .0=K$*Y5BQOBOCN:M538H%GO%@CT;=L-&-(//TIND6[OO,B M/2RUO&>TRF=X,$V.CZWQX&,T_66MM&^,NR6:H6S I88DN*;,V$ M;['JE[=L!AA@P5[J.A+36.6*66J4EUV3" =?[K\M'R"5T7:&#@$NKD%RJ68R M:4+8+F[N7JD :G>?6"Z5=\9=YJK\B '%/.U1$+O2#8^9X[PU0"0):=(B MR<@^PHFY47HZUXA 49669*#_-U!WG_:4#ZEVSH^[XWTGIMNN M*B>GJ(H41K,0>BI7*V9]KRX<\J5"U6SL5:5#OFAB;@2:>DM^4T,4HW!$1.\K:>DO<@OQS5;->+ET!/4J IK2#K, MD $V>2-ME^LEO2SNF24>0K1.9N<)<<^262D45&ES!>6?8"E)'PN,$-P?1.F4 MV3FO]&:G2S&;4G*;E19+#;-8KTLYI/M3-->%FB*68I#S8ME7K-!6T;K@W]5" MA?IMZXO>W(2G>1,R*=?9G*.7M48!(=A&VL UT@!_*1EI'6TMQ:])OP0JK]:K MP/@E!@&4GEK-K,#/]FWI>5$.:$VSL=$Q52%9(QM@1YA^R9O$3D&AH3(X5M;F MH6H?TDU.N6G9&)!-!74PD&' M1"0L?=].%Q19GBADJ67MZ"#[Q3L-2[[BP^(,->E,%#6/4+TN@L@KU@5:@\#U MVUOJ@RK%!UM$R*0*6C+[)C>7]JG8Z2I%6'.C; SV1VHF2B4N8GANN<0%U5U" MJ+OTHW A#N'STFL^:O#K8<+JKH95#OPHI[ZYQ()+'HU@*3; @/$M <0UWDR9 MH!(=11W4N QE/E8\4X02OTGLG9LTO:SO5EF?U^JG(?R>(Y:I_K5XHX10?%FO4?Z7H6PU71!*2?L_190OF+P\20G9UHVH@N[$PS8J=#;<0^$B,H8^1.X6+A;V,C4&LW6(,F'] M_%"Y)&W-2>7P,+ G#-PA?R(,$%7&Q"8ETN;".LC;S>9"EL&)4;C3)>UA0"KV MAC61:"5SPO_+S!A\/!ZAC510'4V#7D._:&,7,@^G6E&%0V]+W.'%P/PX-^WV456H4J?MO ML$":6#GHFH/!>0&8.%;AXX?."&?"*]BA2F_CF;?N-Z#6,N: 5(7"?['1)O7I M)B&9@O<(K.T1-7S(P[A2%@EW )YMD;+YN .H.5_VS09+]QINA$:]:Y#:;;1T MPK): ^E9;E%#/L'1SJ#$3__JY\L:![@Y1!CAG @CFKU-NRZQ(SEA>3*%;GT?T46)RVS@2\';?<40/T?HI %%H6\VRAD@44ALRCD>.'"3TOM M#@5XDP7 _M8VXJO0LDC216T+J"^4AI=YJ\TZ 3$5;Y)_^@2IUH!VOV/GY_>= MGZ7WG\9N_.-A(OVIYRL-<(;+QN'64.%>LN,5E^-51-]T<2-,[ -HKLJJL=-V M,*<_B+J&>1-@FCC&:UE71EN=0VQ7 (\49+2HN%)Q.(1 @N_;RQZA7.>\NEW] MF9S-97M2VF$>^]CHA:)A#:*N .Q8'J"0&AG,T/_X5/F+Y].?HB.F=LOUCQ^D M)-?J*8VNVE6ZZDV94QHE_(=:]+ZD=HJU9J?7+GGQWA0Q]A>>L(IY-:]AD4 G?;5?VOI^.$'XR,<76 OVQO/D$30=GP(6#E'!J$349!*_](() M3DY8A)$&=&"3=#P-@IRAYUG)X&%NU6'=:8#=RUM=#WU%G^"(VH'.+!2 M"T@9?$AR'D@[5\PTVO,#!#;2\2(*\D56Y):>&!-.K._0MXD6) MPI4)@JS[5&@+&?QCKT @+7>Q0J!$&$/T(AL\R15 5!&>)NJ U6^NATBO+\N_ M/8RX52MT)P2("4;\@/IM "=!.*OBZTQO_5TG+BSN3>^-2>HRJ4B)@\)#98FS M<1?5RI*YVY&Y_QJ;6/2 M%3I2%;8;8>"Q5C""%1D<;! 0+W"D0KP O[<1\ .42X1PHX6-0<)\3SPV3;4< M&#B'*,J<#%-Y\(J\"(7'"A12O8AN]4I QHOG$V^;P1ZQC=ZR_^Z0!Y&%/.PV MY$%D(0\LY"%6L/#"[959NKVNE7;WXP=5YRW.;41J79KBM=M=E@/I7? MX)',;GDDD4%0*U\H->J*+)?4Q@7S11XZ6)3V_GHDV@.MCX#=,3BUTIA0#P8N M!#8,K3'-!,:$VDQ>0*I=N;3N0^BML;%/ _?'TI F0A-2HSMZTGELT]K#L:++ M9%@7AO?UJ^OY\->(]PG_V(QT146V,RZFAA:4NO[2*1GVMD,J.!LNX@';];;2/(D9B=_W+%*]H..33/P2 M[KAA(*8IHN']98WG,O"P)KWZ& V&)WUONV.:UH^314F^F^[:CH,=C;@CB^>_ MH)OD/6-N)BZ($5IY7!6E3\NK]($U=@/'U^BQ"=O07>.$5F3I(J,A=&KB2SGH M^-3XGVI@&E^###2%6%;&+Y2970.9 'T W>8X**L8DQ]DJNO MG&A]:.)2!_IRA4WLG"=[,'"-)V2V!FA:S; @I)B+\A5_P&_85M1=M*>T4,X, MX\S'#]%R3=:J"BZWFUR#SCCJ,(_J,ZP;M.OQ[7C--[+4B3V'5FUM2CX$['KT MX,I(;EL949(D6(&K*,5NL]U),DV$12VP8WGH8YG?.I9BDNLUVN4+M=,MM\LE MKJ/4RAVN6>'*K9[:O>Y,I!614C2XM2^M MJNC99GA^5N>/V!1OZ* >EM0+5OX@31D[BD63F\UAU< MVPZP-T]KP__U0S_9)^*A6O.&_?P/;/O-J*?T4^3R6KG+MGRM_9>^UC?/2A+^ M3+WXGQT3&C'6/Q"ZAXT0!#R7F/L)2Z20'%X,!#8O MI 59I)C/0"79JMAHV"*?<>0+CDP? 4=V#=\\>3+\J'T*.+MN49 M>AA/N#U-V=<&M,Q>*%E""D1#%VA,5TO8JD"" EI8,K <:.PI@NW$[5QW6T M=8WA:#LW^I]V XY15\!V25PZK>2P.QZ6RFP!]0;-[20.!8K$O#=OT1 MI814 3:@%[N]BRE+\5**EYFL9++RB,C:LZRDE$JBF)!S0F21G^YJO@.RKEU[ M #V/](\(CR[.F<,E()G%N;K*-3'XR^7E$9.U9?HJY1(;==!XY63^6F>_=T"S M"+Y(9FWL=BZF#(4%99X)2B8HCXBL/0M*F60W? 5DQE)\Q-43;8(Y 3:>TU.!:P]BX[&5,60Q+SS23GDQZ'A%9S/9D9!VC M[(R3[5F'YI,1XMAEDBL#W[8X58W=-L:4NW""I\3$)A.;1T36GL4F,SE/@:P8 MBLV8FIQUX(XI(77; B/ 3$XF.YGL/%&RF.QD9!VC[(R3R7EE(R%)*:G8N-I\ M[#8PIGR%!6:&"4PF,(^(K'W?<,K,17OT9,4K(R6F9F81N+9I6*%243/Z+HC= M1L:4OYC<9'+SV,AB$'O.BE!16Y/W-\E)B1=Z9O#PFLO8M M+UDLT F0%:NSV,*6LA@51DL?@? M1M8QRLR86IN;E6F3L=O)F#(8EIRLU &3G,=$UKXE9YKY9X^>+':A^:.5J0$=L*#6N"2+MF? MX01-?N#:$S*\"X>&A\;$7_KXP873P'##1^T!(IF.)N,W^/'.BDQ%\_%?A;PD M)3C@<0!]2X=Z@G,"UPN Y7.^3;[C0W>R,5KZ,_CR6?Q"QP0^&0G7+VP')AI7 MYM,?/^"W,I_!C[3A,# )?5PI>50;^RHO(J+_Z_R(+\?UZ9\9IBO:TN^[:SN> F')!O+*%P_4,-<2!T-WX./;NV<-&2?>.Z#V/846^K4U=R$8G_?AP';1 MX [9LW"5T;2.:(DWEC-BS[]=A?7%PZM*F?(73]XN#]GW_G(B_3^/"AX0Y70P M0__C4^4O7L#K0B>@=LOUCQ^D)%K=OA>M?-!MP)R)]XDOS@+PM992">YNMHH,@)[EF][+@\\ M9!BYQ"5@NYQA:;;KV"X@C\XY%PZ@2PPOXM8P//07]+%_"F=I9?>MVWG;=N"; MI[5A!O[07/RTNPLM9#Z^ M;N-R#(UZB7,Z-V>TO[.E.S MRX#]7S[M'W]/F%G$I/ >.05P(Z0I_/%IY/N.]S65FLUF20]JR:']E%)<;60\ M02\%]2%P4SKP04J0TWDA+:=XGA?2>4F011')RS3Z)P6?Q7.0'/F3I>@]1R.= MHY]U@8:(#/69G5Z CX#C0Y<3!.[:1&.2RPO;'0++6- +C,\_UHO"RY*B/4'D MS/_WOW.BD/WF<17;G:#ASP7Q(J6$JA8:J +[;@#<.2=D$IS(B\*7Y;Z TSX9 M#$89C+X!1D\Z>N= ,-K_;3!:,CS-M+T 69D='V$FOIAF(!HK'HPI60Q$=QIV5TRE=S*>S^;_@LV0<%DH5S%,XJ :IHNH2-?^=)MHY M%T+HK(,Y)TH,,D^,+ :9.X1,IG?^JMXIG0N'5CPQ/Q$W)<2 J>" 1J)Q(D3\ M,9)23&S83W#2QUIK'@.CD&9J:JQ8-J9D,:>=/H[P]P7F'L56) 3L@1O M,PQO8\6N,26+X>T.\3;]'CEE)W@KY 0Y1_'VF.#61'9_B(G_ FYSY]45R)+! M))X![(F1Q0!VAP KOT=.V;%"*QX68 MS$\P\IHS&BM5B2A;#RIW-5.#9)=4O M@R5:Q(-B90T"#W+*T(7L8C]^+!=3LAAH[A(TV375KX/FH>.CRA/'M.<$,9?8 MF>!T IK4)4I #]G6?>C/(+36H9,4VBB@OW5,,(0NP]Q8<6Q,R6*8NTO,9==4 M.\!<[=@P5['\D8U>=X#E0],T]HB\#'A/A2P&O+L$7G9?]:_OJV0A+Z8&"']T M.!#2!P9?:2F M7;E(;Z00C(MIIKR>&%D,0W=W(R4DA9/NM;#_;/@(CN&S)(27_VN7\OBR/:RT M61P9$.?(0RT@P-40P;Y>73,JJ"GQXK) )W#[P(+>>?/9A/.H2*?(\R*% MLM-G4H9H#-'>@FCOT@6Z)T 3_Q'0*H8%+,T )@,T!F@,T'8/:.^T $W\ M90U-R'&]9"=93"ZA39!DGM9+UVT'&ZNOX5^>ECYG^,?PC^'?6_&/*72[P[]? M5>@8_L6*>V)*%L._'5YS"$FUT6'<\@NTJI9I6&%WI+M"N\:IEN<#?)=0LK4 M7_V^!TYBL,-@YTVPTRE>,F[9)>QTP;-MV9,YLC%]:.'NIEQ'&\$)8#AT4F0Q M'-HI#A65&N.6/>-0$9A:U)6O9ECC/O"8=G1:9#%4VBDJE:1_O&KY$&<*X8BI$O !5S%,R'W&Q9-U/4S+ M,6CZ)$4S"F1ZB$]?7N>YL'7]43:01$3_U_DY6@=HZE_)(GU# TP#G+WTE1/3 MW[@;8 ;X)7=^'NVT;CQ%%/US,T ZP>43&1+GL6I;N=ZF9OO.P_N=6G M\L6,U]#@E3.^N> F')!O+)EX_4,-8L;9^#GT[-K"14OVC>O.'?3[B@OZAO:- M:X )I,O:L/$"BNGU;Z6BK^&/5DP5,=3W%%KHU];/G&C"E+]X\O9^R':("Y03=QISU0\'BQH>IS]%D4T= M]:*A=%F?^\.0?!W&HGW\$*;@NP@=#)>D^Y.ZJ*LH-MSE6) _ZU^B0+7RLS8" M%CH/88B:D)?2B7"0H>'Y+HYQ&P&/TW'I4PT$'I)V:ZV0FAO-ZS=\ M[^.'/AP!%IC(8E2["E,9_=,8KQ8Y]4> M\+'=H[U36YC_+:6[ZT^_4YEC_)GR4J$P@=8C&B:J@_<]9;Q[4<+(>L'E(9-0 M8B).85S"R-KP<.(\*$K)BV30!/?YVC4LS7" ^?+3V*I*[V#7CH:L]\@7,;%J M2L"'(8'N!,/ \[D4CG&8&$B/K*/4B9B =U$ ZX; O M^1O7=/!MJ/>5JP&T$"SV:P>Q7_*_C?UZ/>KI>ZIOZW/R8N1/S#\W][0#_8B$ M9_WY&Z>6R(N_^%SA+QC%8WOA2/A[\&KNWYQ5@O3CL#6PJV>S]./@ICUHW;CN MX]W,-X6N#WK-BXPNN'Y);M1G#6>H9>]+B\ZU?IN7TX_EQGVQ6KNY<7KJO#L8 M#*XR]>O9F2]8=Z[QG*U>*E)N,,C-AZ-)(+CFK%@\N[=[%S=J\3+S**7$84D> M:,4+O\ZKK1CDQ=)C ML?B@5*XFP])-=U9_6 PO;I62,5?0;*;YCES@,[T9N/)N_!NKG;TS*^;8@C4X M<>NUC-^O*()P :H/1E,^NW5D=3Z=+-Q6X2*M-)ZNY.M>H7E=%]V.>0.\5#EC MCN_'\_S]C;YP^KU:^LE\J/&9VB5?+\A"83;L9,W!I"GU[H6[\4.QUE2*I7;I MVLVKW3O/&5W Z509"O6J<#/(9.Q<)3+LV;]M[,>6KU3$[)02M;O:I>FC7>MBVY M-*CF^W=F27@$7!;?L55ZT,2XZ0#QY]T ENY\7[^_GB5LV79'LX#H:/ M@AW4W3ZL/N7N']RK,TT6;OWF?#@MU04A.UWDS.NZT!@ZU=3X?SME-^ MK+5;-[5.1:H6C4I[)KJ7*7OZ?#MH6,4<7V_Z=G-14I[J!=%KJ]+4N;&DFT#4 M&E+U6IE-FY?-"RW0),N:/L[:O1O+F#46TS-8KDI"U6KF057+5&83N;482)<\ M!*.[>=[PL_?MJ9WC"Y5"J3\"0^]932+H3R2-(;_?%"J+6G]S=3 MW[]=.)VTUW](/9B^7.ET(=1*-Y>]LTD&Y >2=:LICEU2E7:K-&[UBB4]E:TX MQEDJ74MKLZ>,+2CWMM<_2QOU6F[4>L[)PR.I@7S6Z"T>?Y"G)9*K8QI!RV^59I-)V.[ZMO3Q>/=S=!T*JFL;/24[K"2 MO6PH9JL]O>W(3X%5N;!GY4Z.?ZS[[4IS(E4SE>$$PA%?F,\S9^W9=2FSN,V6 M+Q_&P67K8BR!9[M>MVX?-?FZ(1I7J;.AJ ;R4VH ;W,7^?N>>>-)HZ>9U-5: MO%EHR'JI*TT?;KU%R[W*""W>#Q;RPSA_X=S#&UL4$L! A0#% @ \*8%50 4 MY,Y>#P 3,$ !4 ( !Z!@ &)I;V8M,C R,C V,S!?9&5F M+GAM;%!+ 0(4 Q0 ( /"F!5524T3(=3@ %H2 P 5 " M 7DH !B:6]F+3(P,C(P-C,P7VQA8BYX;6Q02P$"% ,4 " #PI@55%6"! MC'XE "_1P( %0 @ $A80 8FEO9BTR,#(R,#8S,%]P&UL4$L! A0#% @ \*8%5>'4J'?V!P 7U( H ( ! MTH8 &5X,S$M,2YH=&U02P$"% ,4 " #PI@55"*D>U@X( @4P "@ M @ 'PC@ 97@S,2TR+FAT;5!+ 0(4 Q0 ( /"F!55HI+:@ MJP0 (9 * " 2:7 !E>#,R+3$N:'1M4$L! A0#% M @ \*8%55W(X:R]! 6QH H ( !^9L &5X,S(M,BYH M=&U02P$"% ,4 " #PI@551J\X6T#J #7;0D # @ '> EH 9F]R;3$P+7$N:'1M4$L%!@ * H 90( $B+ 0 $! end